PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28002478-2 2016 In this study we compared in SHR the effects of chronic administration of the centrally acting sympatholytic agent rilmenidine with an angiotensin converting enzyme inhibitor perindopril on the rate of rise and power of the surge in mean arterial pressure (MAP) that occurs with arousal associated with the onset of night. Perindopril 175-186 angiotensin I converting enzyme Homo sapiens 135-164 28856537-0 2017 The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Perindopril 60-71 angiotensin I converting enzyme Homo sapiens 27-30 25980448-2 2015 Clopidogrel inhibits carboxylesterase 1 (CES1), the enzyme responsible for converting prodrug ACE inhibitors (such as ramipril and perindopril) to their active metabolites. Perindopril 131-142 angiotensin I converting enzyme Homo sapiens 94-97 26794937-2 2016 Convers Plus tablet including perindopril erbumine (PE), which is an angiotensin converting enzyme (ACE) inhibitor, and indapamide, which is diuretic, was designed as a combined tablet to succes in the treatment of hypertension. Perindopril 30-50 angiotensin I converting enzyme Homo sapiens 100-103 26794937-2 2016 Convers Plus tablet including perindopril erbumine (PE), which is an angiotensin converting enzyme (ACE) inhibitor, and indapamide, which is diuretic, was designed as a combined tablet to succes in the treatment of hypertension. Perindopril 52-54 angiotensin I converting enzyme Homo sapiens 100-103 27021566-0 2016 Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Perindopril 159-170 angiotensin I converting enzyme Homo sapiens 15-44 27021566-0 2016 Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Perindopril 159-170 angiotensin I converting enzyme Homo sapiens 46-49 26341621-1 2015 Perindopril, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, are established antihypertensive agents with complementary mechanisms of action. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 16-19 24117346-1 2014 The efficacy of the ACE (angiotensin-converting enzyme) inhibitor perindopril in coronary artery disease [EUROPA (European trial on reduction of cardiac events with perindopril in stable coronary artery disease) study] is associated with the rs12050217 A/G single nucleotide polymorphism in the B1 receptor (bradykinin type 1 receptor) gene. Perindopril 165-176 angiotensin I converting enzyme Homo sapiens 25-54 25680080-5 2015 ACE inhibitors such as ramipril, captopril, perindopril, quinapril, lisinopril, enalapril, and trandolapril have been documented to ameliorate the above neurodegenerative disorders. Perindopril 44-55 angiotensin I converting enzyme Homo sapiens 0-3 25131919-1 2014 BACKGROUND: Perindopril and lisinopril are two common ACE inhibitors prescribed for management of hypertension. Perindopril 12-23 angiotensin I converting enzyme Homo sapiens 54-57 25590639-7 2015 The AngloScandinavian Cardiac Outcomes Trial (ASCOT) showed that a combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and CCB amlodipine offered better cardiovascular protection in at-risk hypertensive patients than beta-blocker and thiazide. Perindopril 132-143 angiotensin I converting enzyme Homo sapiens 86-115 25590639-7 2015 The AngloScandinavian Cardiac Outcomes Trial (ASCOT) showed that a combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and CCB amlodipine offered better cardiovascular protection in at-risk hypertensive patients than beta-blocker and thiazide. Perindopril 132-143 angiotensin I converting enzyme Homo sapiens 117-120 25590639-11 2015 A strategy using ACE inhibitors and CCBs, such as perindopril and amlodipine, to target multiple stages in both pathways of cardiovascular disease could effectively reduce cardiovascular risk and lower BP. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 17-20 26075856-3 2015 In 2014 a fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and an diuretic (indapamide) appeared on the Czech market. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 39-42 25985327-7 2015 Perindopril is the only ACE inhibitor to show a real dose-response curve for BP decrease. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 24-27 25985327-11 2015 CONCLUSION: In hypertensive patients, a strategy based on ACE inhibitors with dose-dependent efficacy such as perindopril as optimal treatment should lead both to improved BP control and to a better protection from target organ damage, thereby reducing the incidence of cardiovascular events. Perindopril 110-121 angiotensin I converting enzyme Homo sapiens 58-61 25189490-0 2014 The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Perindopril 76-87 angiotensin I converting enzyme Homo sapiens 41-44 25189490-3 2014 METHODS: We studied 27,492 ACE-inhibitor naive patients randomized to the ACE-inhibitor perindopril or placebo using individual data of 3 clinical trials. Perindopril 88-99 angiotensin I converting enzyme Homo sapiens 74-77 25012003-4 2014 PATIENTS AND METHODS: Patients eligible for burr hole surgery for CSH were randomized into either an ACE inhibitor perindopril 5mg or placebo treatment daily for three months prior to surgery. Perindopril 115-126 angiotensin I converting enzyme Homo sapiens 101-104 24117346-1 2014 The efficacy of the ACE (angiotensin-converting enzyme) inhibitor perindopril in coronary artery disease [EUROPA (European trial on reduction of cardiac events with perindopril in stable coronary artery disease) study] is associated with the rs12050217 A/G single nucleotide polymorphism in the B1 receptor (bradykinin type 1 receptor) gene. Perindopril 66-77 angiotensin I converting enzyme Homo sapiens 20-23 24117346-1 2014 The efficacy of the ACE (angiotensin-converting enzyme) inhibitor perindopril in coronary artery disease [EUROPA (European trial on reduction of cardiac events with perindopril in stable coronary artery disease) study] is associated with the rs12050217 A/G single nucleotide polymorphism in the B1 receptor (bradykinin type 1 receptor) gene. Perindopril 66-77 angiotensin I converting enzyme Homo sapiens 25-54 24117346-1 2014 The efficacy of the ACE (angiotensin-converting enzyme) inhibitor perindopril in coronary artery disease [EUROPA (European trial on reduction of cardiac events with perindopril in stable coronary artery disease) study] is associated with the rs12050217 A/G single nucleotide polymorphism in the B1 receptor (bradykinin type 1 receptor) gene. Perindopril 165-176 angiotensin I converting enzyme Homo sapiens 20-23 25518516-0 2014 [Principles of choice of an angiotensin-converting enzyme inhibitor: specific features of perindopril]. Perindopril 90-101 angiotensin I converting enzyme Homo sapiens 28-57 25902655-8 2014 CONCLUSION: Thus, despite the similar BP reduction the combination of ACE-inhibitor--perindopril with indapamide retard possesses more favorable vascular and metabolic effects compared to combination with hydrochlorothiazide that potentially may account for different prognosis of patients with arterial hypertension on long-term treatment. Perindopril 85-96 angiotensin I converting enzyme Homo sapiens 70-73 25518516-2 2014 This review focuses on the properties and effects of perindopril, which set off it from other ACE inhibitors, going beyond the scope of the classic effects of this group of drugs. Perindopril 53-64 angiotensin I converting enzyme Homo sapiens 94-97 23711055-1 2013 Perindopril is a long acting ACE inhibitor with a 24- hour lasting effect. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 29-32 23933903-2 2013 Among the ACE inhibitor class, the agent perindopril, in particular, has pleiotropic effects that are not equally shared by other ACE inhibitors, including bradykinin site selectivity and subsequent enhancement of nitric oxide and inhibition of endothelial cell apoptosis. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 10-13 23933903-2 2013 Among the ACE inhibitor class, the agent perindopril, in particular, has pleiotropic effects that are not equally shared by other ACE inhibitors, including bradykinin site selectivity and subsequent enhancement of nitric oxide and inhibition of endothelial cell apoptosis. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 130-133 23933903-6 2013 In patients with or at high risk for coronary heart disease who do not have heart failure, or in patients with heart failure with preserved ejection fraction, perindopril should be among the preferred treatment agents in the ACE inhibitor class. Perindopril 159-170 angiotensin I converting enzyme Homo sapiens 225-228 24285767-8 2013 ACE inhibitors evaluated in the studies were captopril, lisinopril, perindopril, quinapril, and ramipril. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 0-3 23681954-15 2013 CONCLUSIONS: Further effective, safe, and sustained 24-h ambulatory BP and office BP reductions were obtained by switching from ACE inhibitors and/or CCBs to a perindopril/amlodipine fixed-dose combination in outpatients with uncontrolled essential hypertension in a practice setting. Perindopril 160-171 angiotensin I converting enzyme Homo sapiens 128-131 23879022-1 2013 Flicker-ERG (FERG) amplitude and glial indices Cg were measured to estimate angiotensin- converting enzyme (ACE) inhibitor Perindopril effect on retinal glial-neuronal interactions in patients with type II diabetes and diabetic retinopathy (DR). Perindopril 123-134 angiotensin I converting enzyme Homo sapiens 108-111 22619549-0 2012 Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite. Perindopril 114-134 angiotensin I converting enzyme Homo sapiens 23-52 22877321-1 2012 BACKGROUND: Fixed-dose combination treatments using an angiotensin-converting enzyme (ACE) inhibitor, such as perindopril, plus a calcium channel blocker (CCB), such as amlodipine, have been endorsed by guidelines because they improve blood pressure control and cardiovascular outcomes in hypertensive patients, while being well tolerated and well adhered to by patients. Perindopril 110-121 angiotensin I converting enzyme Homo sapiens 55-84 22877321-1 2012 BACKGROUND: Fixed-dose combination treatments using an angiotensin-converting enzyme (ACE) inhibitor, such as perindopril, plus a calcium channel blocker (CCB), such as amlodipine, have been endorsed by guidelines because they improve blood pressure control and cardiovascular outcomes in hypertensive patients, while being well tolerated and well adhered to by patients. Perindopril 110-121 angiotensin I converting enzyme Homo sapiens 86-89 22877321-2 2012 OBJECTIVE: This study aimed to assess the blood pressure-lowering effects of fixed-combination perindopril/amlodipine in patients previously treated with an ACE inhibitor and/or a CCB. Perindopril 95-106 angiotensin I converting enzyme Homo sapiens 157-160 23952947-1 2013 We conducted comparative analysis of treatment 52 patients (7 men and 45 women aged 42-64 years, mean age 51.1 years) with I-II degree arterial hypertension (AH) and type 2 diabetes mellitus with the use of angiotensin converting enzyme inhibitor perindopril and with of other drugs. Perindopril 247-258 angiotensin I converting enzyme Homo sapiens 207-236 21466773-5 2011 Recently, some large trials have supported the benefits of combining calcium antagonist, amlodipine, and ACE inhibitor, perindopril, in patients with high cardiovascular risk, stable coronary patients or hypertensive patients. Perindopril 120-131 angiotensin I converting enzyme Homo sapiens 105-108 21688035-0 2012 Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Perindopril 147-158 angiotensin I converting enzyme Homo sapiens 26-55 21688035-0 2012 Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Perindopril 147-158 angiotensin I converting enzyme Homo sapiens 57-60 21599567-2 2011 This review focuses on the specific benefits of the ACE inhibitor perindopril. Perindopril 66-77 angiotensin I converting enzyme Homo sapiens 52-55 21857085-7 2011 The most commonly prescribed ACE-Is were perindopril, lisinopril and chinalapril for inhibition of left ventricular hypertrophy and perindopril, ramipril and chinalapril for inhibition of arterial wall remodeling. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 29-32 21857085-8 2011 The ACE-Is that were used to reduce peripheral vessel resistance included perindopril, lisinopril and trandolapril. Perindopril 74-85 angiotensin I converting enzyme Homo sapiens 4-7 20712529-7 2010 The Perindopril Genetic association (PERGENE) study is a large pharmacogenetic substudy of the randomized placebo-controlled European trial On Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery disease (EUROPA) trial, aimed to assess the feasibility of pharmacogenetic profiling of ACE-inhibitor therapy by perindopril. Perindopril 4-15 angiotensin I converting enzyme Homo sapiens 316-319 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Perindopril 199-210 angiotensin I converting enzyme Homo sapiens 156-159 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Perindopril 199-210 angiotensin I converting enzyme Homo sapiens 194-197 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Perindopril 199-210 angiotensin I converting enzyme Homo sapiens 194-197 20634797-2 2010 We evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril). Perindopril 199-210 angiotensin I converting enzyme Homo sapiens 194-197 20491360-2 2010 The HOPE and EUROPA clinical studies have shown that treatment with the angiotensin-converting enzyme (ACE) inhibitors, ramipril and perindopril, may reduce the occurrence of major cardiovascular events in patients with proven atherosclerotic disease. Perindopril 133-144 angiotensin I converting enzyme Homo sapiens 72-101 20681466-7 2010 Perindopril was the most frequently prescribed ACE inhibitor and atorvastatin the most frequently prescribed statin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 47-50 20491360-2 2010 The HOPE and EUROPA clinical studies have shown that treatment with the angiotensin-converting enzyme (ACE) inhibitors, ramipril and perindopril, may reduce the occurrence of major cardiovascular events in patients with proven atherosclerotic disease. Perindopril 133-144 angiotensin I converting enzyme Homo sapiens 103-106 21694942-3 2010 The angiotensin-converting enzyme (ACE) inhibitor perindopril not only reduces mean arterial pressure but also acts specifically on pulse pressure. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 4-33 19717156-1 2010 BACKGROUND: We have previously shown that the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced aortic diameter by 3-7mm in Marfan syndrome (MFS) patients. Perindopril 92-103 angiotensin I converting enzyme Homo sapiens 46-75 19717156-1 2010 BACKGROUND: We have previously shown that the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced aortic diameter by 3-7mm in Marfan syndrome (MFS) patients. Perindopril 92-103 angiotensin I converting enzyme Homo sapiens 77-80 21694942-3 2010 The angiotensin-converting enzyme (ACE) inhibitor perindopril not only reduces mean arterial pressure but also acts specifically on pulse pressure. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 35-38 19082699-0 2009 The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Perindopril 32-43 angiotensin I converting enzyme Homo sapiens 111-140 19346520-7 2009 CONCLUSION: This study provides strong evidence for a consistent cardiovascular protection with an ACE-inhibitor treatment regimen (perindopril-indapamide) by improving survival and reducing the risk of major cardiovascular events across a broad spectrum of patients with vascular disease. Perindopril 132-143 angiotensin I converting enzyme Homo sapiens 99-102 18950770-0 2009 ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 19005745-1 2009 Editorial to: "Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?" Perindopril 112-123 angiotensin I converting enzyme Homo sapiens 61-64 19082699-8 2009 METHODS: The PERindopril GENEtic association study (PERGENE) is a substudy of the EUROPA trial, a randomized double-blind placebo-controlled multicentre clinical trial which demonstrated a beneficial effect of the ACE-inhibitor perindopril in reducing cardiovascular morbidity and mortality in 12.218 patients with stable coronary artery disease (mean follow-up 4.2 years). Perindopril 13-24 angiotensin I converting enzyme Homo sapiens 214-217 19082699-8 2009 METHODS: The PERindopril GENEtic association study (PERGENE) is a substudy of the EUROPA trial, a randomized double-blind placebo-controlled multicentre clinical trial which demonstrated a beneficial effect of the ACE-inhibitor perindopril in reducing cardiovascular morbidity and mortality in 12.218 patients with stable coronary artery disease (mean follow-up 4.2 years). Perindopril 228-239 angiotensin I converting enzyme Homo sapiens 214-217 19379059-0 2009 Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Perindopril 44-55 angiotensin I converting enzyme Homo sapiens 0-29 19379059-9 2009 The outcome of these and other trials support the concept of specific cardioprotective properties of ACE inhibition by perindopril in addition to the blood pressure-lowering effects, such as anti-atherosclerotic, anti-inflammatory and antithrombotic properties. Perindopril 119-130 angiotensin I converting enzyme Homo sapiens 101-104 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 4-33 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 35-38 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 142-145 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 63-71 angiotensin I converting enzyme Homo sapiens 4-33 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 63-71 angiotensin I converting enzyme Homo sapiens 35-38 19379059-1 2009 The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE. Perindopril 63-71 angiotensin I converting enzyme Homo sapiens 142-145 19379059-2 2009 ACE inhibition by perindopril has two main effects: it inhibits the angiotensin II formation and potentiates bradykinin. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 0-3 19379059-3 2009 Perindopril is one of the ACE inhibitors that has been extensively studied in randomized clinical trials within various patient populations. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 26-29 19379059-6 2009 Therefore, perindopril, as an ACE inhibitor, has an established place in the major clinical treatment guidelines. Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 30-33 19421649-0 2009 Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 57-60 19348394-4 2009 A fixed combination of the ACE inhibitor perindopril and the calcium channel blocker amlodipine proves optimal as has been shown by the results of the ASCOT-BPLA study. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 27-30 19303575-0 2009 Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Perindopril 46-57 angiotensin I converting enzyme Homo sapiens 0-29 19107135-7 2009 However, the blockade of Ang II by perindopril, an angiotensin converting enzyme (ACE) inhibitor, inhibited upregulation of VEGF, and prevented the loss of tight junction proteins. Perindopril 35-46 angiotensin I converting enzyme Homo sapiens 51-80 19107135-7 2009 However, the blockade of Ang II by perindopril, an angiotensin converting enzyme (ACE) inhibitor, inhibited upregulation of VEGF, and prevented the loss of tight junction proteins. Perindopril 35-46 angiotensin I converting enzyme Homo sapiens 82-85 19888783-3 2009 The ACE inhibitor perindopril has proven BP-lowering efficacy as well as protective effects against cardiovascular events among patients with additional cardiovascular risk factors. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 4-7 19791837-4 2009 The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. Perindopril 76-87 angiotensin I converting enzyme Homo sapiens 62-65 19888783-15 2009 CONCLUSIONS: Perindopril 5-10 mg/day lowers BP and PP and improves BP control among hypertensive patients who were previously unresponsive to other ACE inhibitor-based regimens. Perindopril 13-24 angiotensin I converting enzyme Homo sapiens 148-151 18971536-2 2008 In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy. Perindopril 152-163 angiotensin I converting enzyme Homo sapiens 110-141 19032136-2 2008 This article reviews evidence for the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the calcium channel blocker amlodipine. Perindopril 109-120 angiotensin I converting enzyme Homo sapiens 63-92 19032136-2 2008 This article reviews evidence for the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the calcium channel blocker amlodipine. Perindopril 109-120 angiotensin I converting enzyme Homo sapiens 94-97 18971536-8 2008 In conclusion, these results suggest that the angiotensin I-converting enzyme inhibitor perindopril is superior to the calcium channel blocker amlodipine for reducing vascular endothelial dysfunction when co-administered with angiotensin receptor blockers in patients with essential hypertension. Perindopril 88-99 angiotensin I converting enzyme Homo sapiens 46-77 18326980-1 2008 The authors sought to determine whether the angiotensin-converting enzyme (ACE) inhibitor perindopril has beneficial effects on vascular markers of inflammation in patients with the metabolic syndrome when exposed to exercise-induced stress. Perindopril 90-101 angiotensin I converting enzyme Homo sapiens 44-73 18251212-2 2008 The patients were randomly assigned to receive containing a fixed-combination tablet of an ACE inhibitor (perindopril) with a diuretic (indapamide) (4 mg/l,250 mg, n=5569), or placebo (n=5571), administered if needed on top of other blood pressure lowering agents. Perindopril 106-117 angiotensin I converting enzyme Homo sapiens 91-94 18401049-0 2008 [The therapeutic efficiency of complex-ACE inhibitor (perindopril) and traditional antiarrhythmic-treatment for prevention atrial fibrillation paroxysms after successful electric cardio version]. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 39-42 18401049-1 2008 The aim of the study was to estimate the therapeutic efficiency of complex: ACE inhibitor (perindopril) and traditional antiarrhythmic treatment of atrial fibrillation paroxysms after successful electric cardio version for prevention of repeated attacks of atrial fibrillation and for maintenance of normal sinus rhythm in patients. Perindopril 91-102 angiotensin I converting enzyme Homo sapiens 76-79 18326980-1 2008 The authors sought to determine whether the angiotensin-converting enzyme (ACE) inhibitor perindopril has beneficial effects on vascular markers of inflammation in patients with the metabolic syndrome when exposed to exercise-induced stress. Perindopril 90-101 angiotensin I converting enzyme Homo sapiens 75-78 18991817-1 2008 We studied 40 men aged 26 - 59 years (mean age 49.0 +/- 1.9 years) with hypertensive disease (HD) and found that therapy based on the use of angiotensin converting enzyme inhibitor perindopril in young and middle aged patients with stage I and II HD appeared to be not only one of effective methods of correction of elevated arterial pressure (AP) but also of associated with it cognitive abnormalities. Perindopril 181-192 angiotensin I converting enzyme Homo sapiens 141-170 19425365-2 2008 Each group has been stratified into 2 subgroups: patients of subgroups A received an ACE inhibitor perindopril in the complex therapy from the 1st day of disease. Perindopril 99-110 angiotensin I converting enzyme Homo sapiens 85-88 19425365-7 2008 Some similar mechanisms of ischemic lesions of the heart and the brain and a commonness of biochemical "response" to the same medical intervention (the administration of an ACE inhibitor perindopril) in patients of both groups were found. Perindopril 187-198 angiotensin I converting enzyme Homo sapiens 173-176 17923654-3 2007 We sought to examine the effect of the angiotensin-converting-enzyme (ACE) inhibitor perindopril on physical function in elderly people with functional impairment who had no heart failure or left ventricular systolic dysfunction. Perindopril 85-96 angiotensin I converting enzyme Homo sapiens 70-73 18036453-0 2007 The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. Perindopril 76-87 angiotensin I converting enzyme Homo sapiens 36-65 18036453-1 2007 OBJECTIVES: This study sought to examine whether the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitor therapy by perindopril are modified by renal function in patients with stable coronary artery disease. Perindopril 138-149 angiotensin I converting enzyme Homo sapiens 81-110 18036453-1 2007 OBJECTIVES: This study sought to examine whether the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitor therapy by perindopril are modified by renal function in patients with stable coronary artery disease. Perindopril 138-149 angiotensin I converting enzyme Homo sapiens 112-115 17923654-11 2007 INTERPRETATION: Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 27-30 17270296-1 2007 BACKGROUND: The EUROPA trial has demonstrated that an ACE inhibitor perindopril, was able to significantly decrease the risk of major cardiac events in patients with stable coronary heart disease without apparent heart failure. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 54-57 18260912-3 2007 The following mechanisms of stabilization of membranous homeostasis under influence of angiotensin converting enzyme inhibitor perindopril are discussed: action on apoptosis and activation of cells. Perindopril 127-138 angiotensin I converting enzyme Homo sapiens 87-116 17907106-7 2007 This review assesses the literature surrounding the use of the ACE inhibitor perindopril in patients with hypertension and varying degrees of insulin resistance, including the effects of perindopril in preventing the development of diabetes and subsequent cardiovascular morbidity and mortality. Perindopril 77-88 angiotensin I converting enzyme Homo sapiens 63-66 17519062-0 2007 Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Perindopril 66-77 angiotensin I converting enzyme Homo sapiens 52-55 17519062-1 2007 BACKGROUND: The efficacy of the angiotensin-converting enzyme (ACE) inhibitor perindopril in the treatment of hypertension, stable coronary artery disease, and heart failure is well established. Perindopril 78-89 angiotensin I converting enzyme Homo sapiens 32-61 17519062-1 2007 BACKGROUND: The efficacy of the angiotensin-converting enzyme (ACE) inhibitor perindopril in the treatment of hypertension, stable coronary artery disease, and heart failure is well established. Perindopril 78-89 angiotensin I converting enzyme Homo sapiens 63-66 21221198-2 2007 Perindopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, is an established antihypertensive agent administered as a once-daily tablet. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 27-56 21221198-2 2007 Perindopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, is an established antihypertensive agent administered as a once-daily tablet. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 58-61 17140552-0 2007 ACE inhibition with perindopril and endothelial function. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 17140552-2 2007 OBJECTIVES: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Perindopril 63-74 angiotensin I converting enzyme Homo sapiens 253-282 17140552-2 2007 OBJECTIVES: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Perindopril 63-74 angiotensin I converting enzyme Homo sapiens 284-287 17140552-2 2007 OBJECTIVES: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Perindopril 305-316 angiotensin I converting enzyme Homo sapiens 253-282 17140552-2 2007 OBJECTIVES: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Perindopril 305-316 angiotensin I converting enzyme Homo sapiens 284-287 17140552-10 2007 CONCLUSIONS: Abnormal endothelial function occurs in patients with coronary artery disease, and this can be counteracted by angiotensin-converting enzyme inhibition with perindopril. Perindopril 170-181 angiotensin I converting enzyme Homo sapiens 124-153 17305412-4 2007 Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. Perindopril 81-92 angiotensin I converting enzyme Homo sapiens 67-70 17305412-7 2007 Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection. Perindopril 168-179 angiotensin I converting enzyme Homo sapiens 138-141 18219959-0 2007 [The therapy of complicated forms of essential hypertension with the ACE inhibitor perindopril]. Perindopril 83-94 angiotensin I converting enzyme Homo sapiens 69-72 18219959-1 2007 The paper presents a comparison of the influence of angiotensin-converting enzyme (ACE) with high (perindopril) or low (enalapril) affinity to the endothelial renin-angiotensin-aldosterone system on the dynamics of the content of humoral endothelial dysfunction markers in patients with essential hypertension (EH) complicated by ischemic cerebral stroke. Perindopril 99-110 angiotensin I converting enzyme Homo sapiens 52-81 18219959-1 2007 The paper presents a comparison of the influence of angiotensin-converting enzyme (ACE) with high (perindopril) or low (enalapril) affinity to the endothelial renin-angiotensin-aldosterone system on the dynamics of the content of humoral endothelial dysfunction markers in patients with essential hypertension (EH) complicated by ischemic cerebral stroke. Perindopril 99-110 angiotensin I converting enzyme Homo sapiens 83-86 18219959-10 2007 The most prominent therapeutic effect of perindopril is a result of its high affinity to endothelial ACE and the inhibition of bradykinin degradation. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 101-104 17953470-0 2007 ACE inhibition in hypertension: focus on perindopril. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 0-3 17953470-9 2007 In this regard, perindopril, which has relatively high affinity for ACE and true 24-hour duration of action, is one of the most extensively studied ACE inhibitors. Perindopril 16-27 angiotensin I converting enzyme Homo sapiens 68-71 17953470-9 2007 In this regard, perindopril, which has relatively high affinity for ACE and true 24-hour duration of action, is one of the most extensively studied ACE inhibitors. Perindopril 16-27 angiotensin I converting enzyme Homo sapiens 148-151 17106926-1 2006 METHODS: Perindopril (an ACE-I; 4 mg/d) and/or natural IFN (3 MU/L; 3 times a week) were administered for 12 mo to refractory CHC patients, and several indices of serum fibrosis markers were analyzed. Perindopril 9-20 angiotensin I converting enzyme Homo sapiens 25-28 16358672-4 2005 However, the use of newest antihypertensive drugs (the long acting dihydropyridine calcium antagonist amlodipine very often associated to the ACE inhibitor perindopril) in the hypertensive population aged from 40 to 79 years with at least 3 additional risk factors showed significantly lower rates of cardiovascular and total mortalities, cardiovascular events, new diabetes or renal impairment as compared to the atenolol-based combination drug regimen (with thiazide as required). Perindopril 156-167 angiotensin I converting enzyme Homo sapiens 142-145 16342299-6 2006 Inclusion of Perindopril into the essential drug list resulted in an overall increase in utilization of ACE inhibitors: use of captopril and enalapril declined while lisinopril and perindopril increased. Perindopril 13-24 angiotensin I converting enzyme Homo sapiens 104-107 16784179-3 2006 We performed a double-blind, randomised, placebo-controlled study examining the effect of the ACE inhibitor perindopril (4 mg per day) on flow-mediated vasodilatation (FMD) of the brachial artery, arterial blood pressure, glucose homeostasis and inflammatory cytokines. Perindopril 108-119 angiotensin I converting enzyme Homo sapiens 94-97 16410734-4 2006 Patients are randomized to placebo or active treatment starting with the diuretic indapamide and adding the angiotensin-converting enzyme inhibitor perindopril if required. Perindopril 148-159 angiotensin I converting enzyme Homo sapiens 108-137 17083267-6 2006 The ASCOT-BPLA trial underlines the cardiovascular benefit of ACE inhibitors, specifically perindopril, beyond that provided by BP reduction, and potentially reflects a mechanistic feature of the ACE inhibitors. Perindopril 91-102 angiotensin I converting enzyme Homo sapiens 62-65 16710214-6 2006 Perindopril is mentioned among recommended ACE inhibitors despite the fact that it has never been studied in long term trials. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 43-46 17131847-0 2006 [The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril]. Perindopril 106-117 angiotensin I converting enzyme Homo sapiens 31-34 17131847-6 2006 The assessment of haemostasis parameters levels and ACE activity in effect of treatment with perindopril in relation to ACE gene I/D polymorphism. Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 52-55 17131847-6 2006 The assessment of haemostasis parameters levels and ACE activity in effect of treatment with perindopril in relation to ACE gene I/D polymorphism. Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 120-123 17131847-15 2006 Perindopril impairs RAS activity, most in patients with ACE gene II genotype. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 56-59 16451098-1 2006 Perindopril (Coversyl) is a prodrug ester of perindoprilat, an ACE inhibitor. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 63-66 16370923-1 2006 Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 34-37 16881230-0 2006 [Clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme inhibitor perindopril in patients with chronic obstructive lung disease and cor pulmonale]. Perindopril 102-113 angiotensin I converting enzyme Homo sapiens 62-91 16881230-1 2006 AIM: to evaluate the clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril in patients with chronic obstructive lung disease (COLD) and chronic cor pulmonale (CCP). Perindopril 128-139 angiotensin I converting enzyme Homo sapiens 82-111 16881230-1 2006 AIM: to evaluate the clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril in patients with chronic obstructive lung disease (COLD) and chronic cor pulmonale (CCP). Perindopril 128-139 angiotensin I converting enzyme Homo sapiens 113-116 16881230-6 2006 CONCLUSION: It is advisable to include the ACE inhibitor perindopril into complex therapy in patients with CCP in order to correct pulmonary and central hemodynamic disorders. Perindopril 57-68 angiotensin I converting enzyme Homo sapiens 43-46 16405197-6 2005 Pending direct comparator clinical trials between a tissue ACE inhibitor and a plasma ACE inhibitor, both ramipril and perindopril can be recommended for secondary risk prevention, based on the evidence. Perindopril 119-130 angiotensin I converting enzyme Homo sapiens 59-62 16405197-6 2005 Pending direct comparator clinical trials between a tissue ACE inhibitor and a plasma ACE inhibitor, both ramipril and perindopril can be recommended for secondary risk prevention, based on the evidence. Perindopril 119-130 angiotensin I converting enzyme Homo sapiens 86-89 16485516-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 52-81 16485516-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 109-138 16485516-4 2005 Thus, the outcomes of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Perindopril 154-165 angiotensin I converting enzyme Homo sapiens 108-137 16125049-3 2005 Furthermore, recent trials like the Heart Outcomes Prevention Evaluations (HOPE) study and the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) support extending the use of ACE inhibitors to the routine/first-line treatment of patients with an increased global cardiovascular risk. Perindopril 146-157 angiotensin I converting enzyme Homo sapiens 230-233 16125051-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 52-81 16125051-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 109-138 16125051-4 2005 Thus, the outcomes of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Perindopril 154-165 angiotensin I converting enzyme Homo sapiens 108-137 16125052-3 2005 The purpose of this article is to review the large body of evidence, from randomized double-blind clinical trials, that has been gathered in regard to the angiotensin-converting enzyme (ACE) inhibitor perindopril, demonstrating its efficacy in reducing BP, reversing abnormalities of vascular structure and function in patients with essential hypertension, and ultimately preventing cardiovascular events. Perindopril 201-212 angiotensin I converting enzyme Homo sapiens 155-184 16125052-3 2005 The purpose of this article is to review the large body of evidence, from randomized double-blind clinical trials, that has been gathered in regard to the angiotensin-converting enzyme (ACE) inhibitor perindopril, demonstrating its efficacy in reducing BP, reversing abnormalities of vascular structure and function in patients with essential hypertension, and ultimately preventing cardiovascular events. Perindopril 201-212 angiotensin I converting enzyme Homo sapiens 186-189 16116328-8 2005 The administration of perindopril (an ACE inhibitor) prevented the observed increase in bax and bcl-XS levels and attenuated (50% decrease, P<0.05) the effect of isoproterenol on DNA fragmentation. Perindopril 22-33 angiotensin I converting enzyme Homo sapiens 38-41 16335885-0 2005 Effect of the angiotensin-converting enzyme inhibitor perindopril on 24-hour blood pressure in patients with lacunar infarction: comparison between dippers and non-dippers. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 14-43 15803314-1 2005 PURPOSE: The production of aldosterone in the heart is suppressed by the angiotensin-converting enzyme (ACE) inhibitor perindopril in patients with congestive heart failure (CHF). Perindopril 119-130 angiotensin I converting enzyme Homo sapiens 73-102 15803314-1 2005 PURPOSE: The production of aldosterone in the heart is suppressed by the angiotensin-converting enzyme (ACE) inhibitor perindopril in patients with congestive heart failure (CHF). Perindopril 119-130 angiotensin I converting enzyme Homo sapiens 104-107 15860521-1 2005 AIMS: The aim of this study was to assess the effect of the angiotensin converting enzyme inhibitor perindopril on cardiovascular events in diabetic patients with coronary artery disease. Perindopril 100-111 angiotensin I converting enzyme Homo sapiens 60-89 16335885-1 2005 Antihypertensive therapy based on the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced the incidence of recurrent stroke in the Perindopril Protection against Recurrent Stroke Study (PROGRESS). Perindopril 84-95 angiotensin I converting enzyme Homo sapiens 38-67 16335885-1 2005 Antihypertensive therapy based on the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced the incidence of recurrent stroke in the Perindopril Protection against Recurrent Stroke Study (PROGRESS). Perindopril 84-95 angiotensin I converting enzyme Homo sapiens 69-72 16335885-1 2005 Antihypertensive therapy based on the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced the incidence of recurrent stroke in the Perindopril Protection against Recurrent Stroke Study (PROGRESS). Perindopril 145-156 angiotensin I converting enzyme Homo sapiens 38-67 16335885-1 2005 Antihypertensive therapy based on the angiotensin-converting enzyme (ACE) inhibitor perindopril reduced the incidence of recurrent stroke in the Perindopril Protection against Recurrent Stroke Study (PROGRESS). Perindopril 145-156 angiotensin I converting enzyme Homo sapiens 69-72 16075030-9 2005 The blood pressure lowering arm will investigate the possible reduction in major vascular disease in patients with Type II diabetes whether or not they have hypertension, and the possible benefits of blood pressure lowering in such patients already receiving background therapy with the ACE inhibitor perindopril. Perindopril 301-312 angiotensin I converting enzyme Homo sapiens 287-290 16279041-0 2005 [Use of the ACE inhibitor perindopril in patients with chronic obstructive lung diseases, complicated by cor pulmonale]. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 12-15 15723572-0 2005 Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 0-29 15723572-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 52-81 15723572-1 2005 Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 109-138 15723572-4 2005 Thus, the outcome of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Perindopril 153-164 angiotensin I converting enzyme Homo sapiens 107-136 15882297-7 2005 RESULTS: Following treatment with the ACE inhibitor, perindopril, renal clearance of NMN was increased (+96%) (P < 0.05). Perindopril 53-64 angiotensin I converting enzyme Homo sapiens 38-41 15857358-6 2005 The ACE inhibitor, perindopril, has been shown to decrease arterial stiffness, largely independently of any effect on peripheral blood pressure. Perindopril 19-30 angiotensin I converting enzyme Homo sapiens 4-7 16197648-2 2005 The PICXEL study showed that a strategy based on a low-dose combination of the ACE inhibitor perindopril and the diuretic indapamide was significantly more effective than the ACE inhibitor enalapril alone in reducing left ventricular mass. Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 79-82 16197648-2 2005 The PICXEL study showed that a strategy based on a low-dose combination of the ACE inhibitor perindopril and the diuretic indapamide was significantly more effective than the ACE inhibitor enalapril alone in reducing left ventricular mass. Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 175-178 16197649-5 2005 Impressive results have been obtained with a low-dose combination of the ACE-inhibitor perindopril and the diuretic indapamide, which not only gave superior reductions in blood pressure to enalapril, but also a 24% greater reduction in albumin excretion. Perindopril 87-98 angiotensin I converting enzyme Homo sapiens 73-76 16279041-1 2005 The purpose of the study was to evaluate hemodynamic effects and safety of the ACE inhibitor perindopril in treatment of secondary pulmonary hypertension (PH) in patients with chronic obstructive bronchitis (COB). Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 79-82 16279041-7 2005 According to the authors, the ACE inhibitor perindopril may be recommended for correction of hemodynamic disturbances in cases of chronic cor pulmonale in patients with chronic obstructive lung diseases. Perindopril 44-55 angiotensin I converting enzyme Homo sapiens 30-33 15744357-3 2004 Apart from appropriate clinical measures to be taken, the choice of the ACE inhibitor seems to be of crucial importance as some (fosinopril, perindopril) produce less hypotension than others. Perindopril 141-152 angiotensin I converting enzyme Homo sapiens 72-75 15256675-0 2004 Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 10-39 15567997-7 2004 The EUROPA study assessed the effects of the ACE inhibitor perindopril in a larger group of lower risk patients with established stable cardiovascular disease. Perindopril 59-70 angiotensin I converting enzyme Homo sapiens 45-48 15498085-1 2004 AIMS: To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 66-69 15449186-0 2004 Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. Perindopril 57-68 angiotensin I converting enzyme Homo sapiens 15-46 15449186-2 2004 In particular, the ACE inhibitor, perindopril, significantly inhibits tumor growth and angiogenesis in hepatocellular carcinoma cells along with suppression of the VEGF level. Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 19-22 15449186-12 2004 The ACE inhibitor perindopril has clinical potential as a useful antitumor agent. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 4-7 15673060-0 2004 Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 111-140 15673060-0 2004 Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 142-145 15673060-11 2004 Perindopril reduced fibrinogen levels in ACE II homozygotes due to its more potent inhibitory action on the renin-angiotensin system in such patients. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 41-44 15166388-3 2004 We examined the effect of the angiotensin-converting enzyme (ACE) inhibitor perindopril on cerebral vasomotor reactivity to acetazolamide in patients with lacunar cerebral infarction. Perindopril 76-87 angiotensin I converting enzyme Homo sapiens 61-64 15477791-0 2004 [Assessment of effects of angiotensin converting enzyme inhibitor perindopril on function of endothelium of arterial vessels in patients with ischemic heart disease and hypertension]. Perindopril 66-77 angiotensin I converting enzyme Homo sapiens 26-55 15222615-7 2004 In secondary prevention of stroke, the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) demonstrated that a blood pressure-lowering regimen, involving a angiotensin-converting enzyme inhibitor and a diuretic, reduced the risks of stroke of 28% and of other major vascular events of 26% among individuals with a history of cerebrovascular disease. Perindopril 39-50 angiotensin I converting enzyme Homo sapiens 169-198 14751661-11 2004 CONCLUSIONS: These results suggest that ACE inhibition by perindopril improves myocardial angiogenesis in this animal model of human metabolic syndrome. Perindopril 58-69 angiotensin I converting enzyme Homo sapiens 40-43 15083634-8 2004 Treatment with the ACE inhibitor perindopril with discretionary use of the diuretic indapamide produced reductions in the risk of recurrent stroke in patients with diabetes that were at least as great as those achieved in patients without diabetes. Perindopril 33-44 angiotensin I converting enzyme Homo sapiens 19-22 15229761-1 2004 BACKGROUND: Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, is a well-recognized antihypertensive drug. Perindopril 12-23 angiotensin I converting enzyme Homo sapiens 28-57 15229761-1 2004 BACKGROUND: Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, is a well-recognized antihypertensive drug. Perindopril 12-23 angiotensin I converting enzyme Homo sapiens 59-62 15077477-4 2004 In the EUROPA trial a lower risk population--symptomfree coronary patients--were treated by perindopril, and it was proven also in this cohort, that the long term ACE inhibitor treatment decreased the combined endpoint of cardiovascular mortality, myocardial infarction and resuscitated sudden death. Perindopril 92-103 angiotensin I converting enzyme Homo sapiens 163-166 12929469-10 2003 This is the case, for instance, for the fixed very-low-dose combination of the ACE inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), as this preparation is very effective in decreasing blood pressure while maintaining a tolerability that is similar to that of placebo. Perindopril 93-104 angiotensin I converting enzyme Homo sapiens 79-82 12925049-2 2003 The aim of this study was to establish if ANP increases UAER in microalbuminuric subjects with Type 2 diabetes and to examine whether the albuminuric action of ANP was inhibited by pre-treatment with the ACE-inhibitor perindopril. Perindopril 218-229 angiotensin I converting enzyme Homo sapiens 204-207 14748202-2 2003 The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the angiotensin-converting-enzyme inhibitor perindopril reduces cardiovascular risk in a population with stable coronary heart disease and no apparent heart failure, whatever the associated cardiovascular risk. Perindopril 231-242 angiotensin I converting enzyme Homo sapiens 191-220 13678872-2 2003 We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Perindopril 38-49 angiotensin I converting enzyme Homo sapiens 24-27 12808303-1 2003 Objective of the present study was to investigate the elimination kinetics of quinaprilat and perindoprilat, the active metabolites of angiotensin-converting enzyme (ACE) inhibitors quinapril and perindopril, in hypertensive patients with renal failure under haemodialysis to evaluate the appropriate duration of off-dose of these drugs before starting of low-density lipoprotein (LDL) apheresis. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 135-164 12808303-1 2003 Objective of the present study was to investigate the elimination kinetics of quinaprilat and perindoprilat, the active metabolites of angiotensin-converting enzyme (ACE) inhibitors quinapril and perindopril, in hypertensive patients with renal failure under haemodialysis to evaluate the appropriate duration of off-dose of these drugs before starting of low-density lipoprotein (LDL) apheresis. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 166-169 12953851-3 2003 Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) was designed to determine the effects of an angiotensin-converting enzyme (ACE) inhibitor-based blood pressure-lowering regimen on the risk of stroke among individuals with a prior stroke or transient ischaemic attack (TIA). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 109-138 12953851-3 2003 Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) was designed to determine the effects of an angiotensin-converting enzyme (ACE) inhibitor-based blood pressure-lowering regimen on the risk of stroke among individuals with a prior stroke or transient ischaemic attack (TIA). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 140-143 12677092-7 2002 Studies have found that the ACE inhibitor, perindopril (PE), which is a potent inhibitor of experimental HCC growth and angiogenesis, is associated with the suppression of VEGF at a clinically comparable dose. Perindopril 43-54 angiotensin I converting enzyme Homo sapiens 28-31 12708881-9 2003 Any participant in whom ACE inhibition is thought to be indicated is provided with background perindopril therapy. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 24-27 12677092-7 2002 Studies have found that the ACE inhibitor, perindopril (PE), which is a potent inhibitor of experimental HCC growth and angiogenesis, is associated with the suppression of VEGF at a clinically comparable dose. Perindopril 56-58 angiotensin I converting enzyme Homo sapiens 28-31 12224817-2 2002 A crossover study was performed to determine if ACE inhibition with perindopril (4 mg/day) for 4 weeks decreases serum ADMA concentration and plasma von Willebrand factor (vWF) level (a marker of endothelial injury) in 11 patients with NIDDM. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 48-51 12231595-1 2002 OBJECTIVE: To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 42-71 12374901-4 2002 METHODS: The PERFECT study is a study nested within the EUROPA trial, a three year double-blind, multi-centre, placebo-controlled randomised study that aims at studying the effect of the ACE-inhibitor Perindopril on morbidity and mortality in over 12,000 patients with stable coronary artery disease without clinical heart failure. Perindopril 201-212 angiotensin I converting enzyme Homo sapiens 187-190 12008175-6 2002 The levels of aldosterone as well as ACE activity were significantly lower at the anterior interventricular vein and coronary sinus in the perindopril group than in the placebo group. Perindopril 139-150 angiotensin I converting enzyme Homo sapiens 37-40 12008175-8 2002 Perindopril suppressed cardiac aldosterone production by mainly suppressing cardiac ACE activity in patients with heart failure. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 84-87 12008175-9 2002 Thus, aldosterone production is activated in the failing ventricle and is suppressed by perindopril mainly via the suppression of cardiac ACE activity in patients with heart failure. Perindopril 88-99 angiotensin I converting enzyme Homo sapiens 138-141 12374901-14 2002 CONCLUSION: The findings of the PERFECT study may help to understand and explain the effects of ACE inhibition, in particular Perindopril, on cardiovascular morbidity and mortality. Perindopril 126-137 angiotensin I converting enzyme Homo sapiens 96-99 12076191-1 2002 Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 29-32 11901904-5 2002 The PROGRESS study shows that the decrease in blood pressure, in response to an ACE inhibitor/diuretic bitherapy (perindopril/indapamide), in patients with previous minor stroke or transient ischaemic attack, reduces significantly the risk of recurrent stroke. Perindopril 114-125 angiotensin I converting enzyme Homo sapiens 80-83 12240792-0 2002 ACE inhibitors in heart failure--switching from enalapril to perindopril. Perindopril 61-72 angiotensin I converting enzyme Homo sapiens 0-3 11901939-1 2002 The "Perindopril protection against recurrent stroke study" (PROGRESS) demonstrated that for patients with a history of stroke or transient ischaemic attack during the previous 5 years, a blood-pressure-lowering regimen based on the combination of a diuretic and an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of stroke recurrence (fatal and non-fatal) by 28% (95%-CI: 17-38). Perindopril 5-16 angiotensin I converting enzyme Homo sapiens 266-295 11901939-1 2002 The "Perindopril protection against recurrent stroke study" (PROGRESS) demonstrated that for patients with a history of stroke or transient ischaemic attack during the previous 5 years, a blood-pressure-lowering regimen based on the combination of a diuretic and an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of stroke recurrence (fatal and non-fatal) by 28% (95%-CI: 17-38). Perindopril 5-16 angiotensin I converting enzyme Homo sapiens 297-300 11984065-4 2002 Studies have found that an ACE inhibitor, perindopril, is a potent inhibitor of experimental tumor development and angiogenesis at a clinically comparable dose. Perindopril 42-53 angiotensin I converting enzyme Homo sapiens 27-30 11882622-5 2002 Perindopril decreased plasma ACE by 70% and the plasma angiotensin II to angiotensin I ratio by 57% and reduced vascular ACE to approximately 65% of control levels in both endothelium and adventitia. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 29-32 11882622-5 2002 Perindopril decreased plasma ACE by 70% and the plasma angiotensin II to angiotensin I ratio by 57% and reduced vascular ACE to approximately 65% of control levels in both endothelium and adventitia. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 121-124 12043242-0 2002 [Polymorphism of the ACE gene, structural-functional state of the left ventricle in patients with post-infarction cardiac failure and effects of the ACE-inhibitor Perindopril]. Perindopril 163-174 angiotensin I converting enzyme Homo sapiens 21-24 11855668-1 2002 The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD). Perindopril 113-124 angiotensin I converting enzyme Homo sapiens 72-101 11855668-1 2002 The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD). Perindopril 113-124 angiotensin I converting enzyme Homo sapiens 103-106 11855668-7 2002 The extent of reduction of left ventricular wall motion score by perindopril was closely correlated with that of inhibition of serum ACE activities (P<0.01) and with that of increase in plasma bradykinin concentrations (P<0.05). Perindopril 65-76 angiotensin I converting enzyme Homo sapiens 133-136 12138805-3 2002 The PROGRESS trial demonstrates that antihypertensive therapy of patients with the history of acute cerebral circulation disorder with ACE inhibitor perindopril is effective in secondary prophylaxis in such patients. Perindopril 149-160 angiotensin I converting enzyme Homo sapiens 135-138 12043242-0 2002 [Polymorphism of the ACE gene, structural-functional state of the left ventricle in patients with post-infarction cardiac failure and effects of the ACE-inhibitor Perindopril]. Perindopril 163-174 angiotensin I converting enzyme Homo sapiens 149-152 12043242-1 2002 AIM: To evaluate relationships between structural-functional state of the left ventricle (LV) and genotype of angiotensin converting enzyme (ACE) gene in patients with postinfarction chronic cardiac failure (CCF) and effects of ACE inhibitor perindopril on hemodynamics depending on ACE gene polymorphism. Perindopril 242-253 angiotensin I converting enzyme Homo sapiens 110-139 12043242-1 2002 AIM: To evaluate relationships between structural-functional state of the left ventricle (LV) and genotype of angiotensin converting enzyme (ACE) gene in patients with postinfarction chronic cardiac failure (CCF) and effects of ACE inhibitor perindopril on hemodynamics depending on ACE gene polymorphism. Perindopril 242-253 angiotensin I converting enzyme Homo sapiens 141-144 12043242-1 2002 AIM: To evaluate relationships between structural-functional state of the left ventricle (LV) and genotype of angiotensin converting enzyme (ACE) gene in patients with postinfarction chronic cardiac failure (CCF) and effects of ACE inhibitor perindopril on hemodynamics depending on ACE gene polymorphism. Perindopril 242-253 angiotensin I converting enzyme Homo sapiens 228-231 12043242-1 2002 AIM: To evaluate relationships between structural-functional state of the left ventricle (LV) and genotype of angiotensin converting enzyme (ACE) gene in patients with postinfarction chronic cardiac failure (CCF) and effects of ACE inhibitor perindopril on hemodynamics depending on ACE gene polymorphism. Perindopril 242-253 angiotensin I converting enzyme Homo sapiens 228-231 12043242-18 2002 Perindopril is most effective in DD-genotype of ACE gene. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 48-51 11903319-18 2001 Central pulse pressure was improved following 1 month treatment with an ACE inhibitor or beta-adrenoceptor blockade following a decrease in arterial wave reflections with perindopril and a higher decrease in regional aortic stiffness with atenolol. Perindopril 171-182 angiotensin I converting enzyme Homo sapiens 72-75 11903323-10 2001 These reductions were all magnified by approximately 50% in a subgroup of patients in whom the angiotensin-converting enzyme inhibitor perindopril was routinely combined with the diuretic indapamide. Perindopril 135-146 angiotensin I converting enzyme Homo sapiens 95-124 11713850-3 2001 The use of perindopril/indapamide is an example of such a combination which contains 2 mg of the angiotensin converting enzyme inhibitor perindopril and 0.625 mg of the diuretic indapamide, these doses being respectively half and a quarter of the usual doses in monotherapy. Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 97-126 11751733-13 2001 The present study demonstrates that chronic administration of the ACE inhibitor perindopril increases the magnitude of the flow-dependent dilatation and restores the flow-dependent increase in compliance and distensibility of the radial artery evaluated at stable shear stress. Perindopril 80-91 angiotensin I converting enzyme Homo sapiens 66-69 11591356-1 2001 Perindopril erbumine is a once-daily angiotensin-converting enzyme (ACE) inhibitor that effectively lowers systolic and diastolic blood pressure (BP) in patients with mild-to-moderate hypertension. Perindopril 0-20 angiotensin I converting enzyme Homo sapiens 37-66 11591356-1 2001 Perindopril erbumine is a once-daily angiotensin-converting enzyme (ACE) inhibitor that effectively lowers systolic and diastolic blood pressure (BP) in patients with mild-to-moderate hypertension. Perindopril 0-20 angiotensin I converting enzyme Homo sapiens 68-71 11591356-2 2001 Converted from the prodrug ester perindopril, the active diacid perindoprilat is distributed rapidly and extensively, primarily to tissues with high ACE activity. Perindopril 33-44 angiotensin I converting enzyme Homo sapiens 149-152 11591357-3 2001 In a review of the worldwide literature of the efficacy and safety of perindopril erbumine for the treatment of patients with CHF, once-daily treatment with this ACE inhibitor was shown to be effective in patients with CHF of all severities. Perindopril 70-90 angiotensin I converting enzyme Homo sapiens 162-165 11591359-6 2001 Cough, the most common ACE inhibitor-associated side effect, is also the most common clinical adverse event reported for perindopril, but <2% of perindopril-treated patients discontinue therapy because of cough. Perindopril 148-159 angiotensin I converting enzyme Homo sapiens 23-26 11591359-7 2001 Other adverse events often associated with ACE inhibitors, first-dose hypotension and hyperkalemia, appear to occur less often with perindopril than with other agents in this class. Perindopril 132-143 angiotensin I converting enzyme Homo sapiens 43-46 11806464-1 2001 UNLABELLED: We conducted a randomised, double-blind multicentre trial to compare the efficacy of the inhibitor of the angiotensin-converting enzyme (ACE) perindopril (P) with nitrendipine (N) in incipient diabetic nephropathy. Perindopril 154-165 angiotensin I converting enzyme Homo sapiens 118-147 11806464-1 2001 UNLABELLED: We conducted a randomised, double-blind multicentre trial to compare the efficacy of the inhibitor of the angiotensin-converting enzyme (ACE) perindopril (P) with nitrendipine (N) in incipient diabetic nephropathy. Perindopril 154-165 angiotensin I converting enzyme Homo sapiens 149-152 12025949-13 2001 ACE inhibition with perindopril during this short-term treatment had no significant effects. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 11713850-3 2001 The use of perindopril/indapamide is an example of such a combination which contains 2 mg of the angiotensin converting enzyme inhibitor perindopril and 0.625 mg of the diuretic indapamide, these doses being respectively half and a quarter of the usual doses in monotherapy. Perindopril 137-148 angiotensin I converting enzyme Homo sapiens 97-126 11330885-7 2001 INTERVENTIONS: Patients were treated for 6 months, starting with perindopril (angiotensin converting enzyme (ACE) inhibitor) 4 mg once daily (OD), increased to 8 mg OD, and combined to diuretic (indapamide 2.5 mg OD) if BP was uncontrolled (> 140/90 mmHg). Perindopril 65-76 angiotensin I converting enzyme Homo sapiens 78-107 11399702-2 2001 The purpose of this prospective study was to determine whether long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril improves respiratory muscle strength in patients with chronic heart failure. Perindopril 136-147 angiotensin I converting enzyme Homo sapiens 90-119 11399702-2 2001 The purpose of this prospective study was to determine whether long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril improves respiratory muscle strength in patients with chronic heart failure. Perindopril 136-147 angiotensin I converting enzyme Homo sapiens 121-124 11399702-10 2001 CONCLUSIONS: In patients with chronic heart failure, long-term therapy with the ACE inhibitor perindopril improved respiratory muscle strength, as indicated by significant increases in PImax and PEmax. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 80-83 11497208-4 2001 Among those in the last group is the Perindopril Protection Against Recurrent Stroke Study (PROGRESS), which examines the effects of perindopril-based ACE inhibitor therapy in both normotensive and hypertensive patients who have survived a stroke. Perindopril 37-48 angiotensin I converting enzyme Homo sapiens 151-154 11497208-4 2001 Among those in the last group is the Perindopril Protection Against Recurrent Stroke Study (PROGRESS), which examines the effects of perindopril-based ACE inhibitor therapy in both normotensive and hypertensive patients who have survived a stroke. Perindopril 133-144 angiotensin I converting enzyme Homo sapiens 151-154 11330885-7 2001 INTERVENTIONS: Patients were treated for 6 months, starting with perindopril (angiotensin converting enzyme (ACE) inhibitor) 4 mg once daily (OD), increased to 8 mg OD, and combined to diuretic (indapamide 2.5 mg OD) if BP was uncontrolled (> 140/90 mmHg). Perindopril 65-76 angiotensin I converting enzyme Homo sapiens 109-112 11230284-8 2001 An angiotensin-converting enzyme (ACE) inhibitor (perindopril) significantly inhibited neointimal formation after balloon injury compared with vehicle (P:<0.05). Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 3-32 11230284-8 2001 An angiotensin-converting enzyme (ACE) inhibitor (perindopril) significantly inhibited neointimal formation after balloon injury compared with vehicle (P:<0.05). Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 34-37 11230284-13 2001 Given the strong mitogenic activity of HGF on endothelial cells, improvement of endothelial dysfunction by perindopril might be due to increased local HGF expression through enhancement of reendothelialization after balloon injury, in addition to its direct effect, ACE inhibition. Perindopril 107-118 angiotensin I converting enzyme Homo sapiens 266-269 11181984-3 2001 In a prospective double-blind randomized study, normotensive patients with type 1 diabetes mellitus with normal serum creatinine and no microalbuminuria were treated with either placebo or perindopril, an ACE inhibitor. Perindopril 189-200 angiotensin I converting enzyme Homo sapiens 205-208 14728020-15 2001 Long term treatment with an ACE inhibitor, perindopril, was associated with a decrease in blood pressure and aortic PWV in patients with essential hypertension. Perindopril 43-54 angiotensin I converting enzyme Homo sapiens 28-31 11398915-1 2001 UNLABELLED: Perindopril erbumine (perindopril) is a prodrug ester of perindoprilat, an angiotensin converting enzyme (ACE) inhibitor. Perindopril 12-32 angiotensin I converting enzyme Homo sapiens 87-116 11398915-11 2001 Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 65-68 11398915-12 2001 CONCLUSIONS: Perindopril is a well tolerated ACE inhibitor that is significantly better than captopril (in terms of response rates) in the treatment of hypertension, and as effective as other ACE inhibitors. Perindopril 13-24 angiotensin I converting enzyme Homo sapiens 45-48 11398915-12 2001 CONCLUSIONS: Perindopril is a well tolerated ACE inhibitor that is significantly better than captopril (in terms of response rates) in the treatment of hypertension, and as effective as other ACE inhibitors. Perindopril 13-24 angiotensin I converting enzyme Homo sapiens 192-195 11465878-1 2001 The fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Perindopril 52-63 angiotensin I converting enzyme Homo sapiens 38-41 11398915-1 2001 UNLABELLED: Perindopril erbumine (perindopril) is a prodrug ester of perindoprilat, an angiotensin converting enzyme (ACE) inhibitor. Perindopril 12-32 angiotensin I converting enzyme Homo sapiens 118-121 11398915-1 2001 UNLABELLED: Perindopril erbumine (perindopril) is a prodrug ester of perindoprilat, an angiotensin converting enzyme (ACE) inhibitor. Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 87-116 11398915-1 2001 UNLABELLED: Perindopril erbumine (perindopril) is a prodrug ester of perindoprilat, an angiotensin converting enzyme (ACE) inhibitor. Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 118-121 11208485-12 2001 "Tissue type" ACE-Is, e.g. quinapril or perindopril acted through accumulation of endogenous Bk. Perindopril 40-51 angiotensin I converting enzyme Homo sapiens 14-17 11728296-1 2000 Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 26-55 10948081-11 2000 Long-term therapy with the ACE inhibitor perindopril induces structural repair of coronary arterioles that is mainly characterized by the regression of periarteriolar fibrosis and associated with a marked improvement in coronary reserve. Perindopril 41-52 angiotensin I converting enzyme Homo sapiens 27-30 11085284-0 2000 Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 14-43 11085284-6 2000 The measurements were carried out before therapy, after 1 week of placebo administration, and after 1 week and after 1 month of ACE-inhibitor perindopril therapy in a once-daily dose of 4 mg. Perindopril 142-153 angiotensin I converting enzyme Homo sapiens 128-131 10938492-12 2000 CONCLUSION: A low dose of perindopril is well-tolerated at initiation of ACE inhibitor therapy in patients with chronic heart failure and causes less first-dose hypotension than a low dose of enalapril. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 73-76 10822319-0 2000 Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly. Perindopril 47-58 angiotensin I converting enzyme Homo sapiens 33-36 10822319-1 2000 To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly, patients >65 years of age with supine diastolic blood pressure (BP) > or =90 and < or =110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multicentre, randomised, double-blind, parallel group design. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 47-76 10822319-1 2000 To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly, patients >65 years of age with supine diastolic blood pressure (BP) > or =90 and < or =110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multicentre, randomised, double-blind, parallel group design. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 78-81 10935667-4 1999 AIMS: The aims of this trial are to assess the potential benefits of the ACE inhibitor perindopril to treat chronic heart failure in elderly people, in the absence of any major left ventricular systolic dysfunction. Perindopril 87-98 angiotensin I converting enzyme Homo sapiens 73-76 10604482-4 1999 Accordingly, the aim of this study was to determine the effects of an ACE inhibitor (perindopril) and an Ang-II receptor antagonist (losartan) on fibrinolytic kinetics. Perindopril 85-96 angiotensin I converting enzyme Homo sapiens 70-73 10608480-2 1999 OBJECTIVE: The primary aim of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) is to determine the effects of a long-term angiotensin converting enzyme (ACE)-inhibitor-based blood-pressure-lowering regimen on the risk of stroke among patients with a history of stroke or transient ischaemic attack (TIA). Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 142-171 10608480-2 1999 OBJECTIVE: The primary aim of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) is to determine the effects of a long-term angiotensin converting enzyme (ACE)-inhibitor-based blood-pressure-lowering regimen on the risk of stroke among patients with a history of stroke or transient ischaemic attack (TIA). Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 173-176 10473021-3 1999 The fixed low-dose combination of perindopril 2mg with indapamide 0.625mg combines an angiotensin converting enzyme (ACE) inhibitor with a non-thiazide diuretic. Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 86-115 10473021-3 1999 The fixed low-dose combination of perindopril 2mg with indapamide 0.625mg combines an angiotensin converting enzyme (ACE) inhibitor with a non-thiazide diuretic. Perindopril 34-45 angiotensin I converting enzyme Homo sapiens 117-120 10800878-0 2000 The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson"s disease. Perindopril 51-62 angiotensin I converting enzyme Homo sapiens 4-33 10800878-0 2000 The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson"s disease. Perindopril 51-62 angiotensin I converting enzyme Homo sapiens 35-38 10800878-5 2000 AIMS: We performed a double blind placebo controlled crossover pilot study in seven patients to investigate the effect of the ACE inhibitor, perindopril on the clinical features of moderately severe Parkinson"s disease. Perindopril 141-152 angiotensin I converting enzyme Homo sapiens 126-129 10800878-9 2000 CONCLUSIONS: These results suggest that ACE inhibitors such as perindopril may have a place in the management of motor fluctuations and dyskinesia in Parkinson"s disease and justify further study. Perindopril 63-74 angiotensin I converting enzyme Homo sapiens 40-43 10583036-1 1999 AIMS: To assess the persistence of the antihypertensive effect of the ACE-inhibitor perindopril after one missed dose. Perindopril 84-95 angiotensin I converting enzyme Homo sapiens 70-73 9571355-1 1998 OBJECTIVE: To compare the effects of the ACE inhibitor perindopril and the beta-blocker carvedilol on blood pressure and endothelial functions in NIDDM patients with hypertension. Perindopril 55-66 angiotensin I converting enzyme Homo sapiens 41-44 10069433-1 1999 Because S-perindopril enantiomer is the eutomer which is responsible for the angiotensin-converting enzyme inhibition activity, it is necessary to develop a reliable method for its assay from its distomer, the R-enantiomer. Perindopril 8-21 angiotensin I converting enzyme Homo sapiens 77-106 9752894-1 1998 The angiotensin converting enzyme inhibitor perindopril and the diuretic indapamide have been shown to be effective antihypertensive agents in patients with chronic renal failure. Perindopril 44-55 angiotensin I converting enzyme Homo sapiens 4-33 9867064-1 1998 We conducted a 3-year randomized placebo-controlled double-blind study to determine the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril (PE) on the progress of renal function and histology in subjects with diabetes and microalbuminuria. Perindopril 149-160 angiotensin I converting enzyme Homo sapiens 134-137 9867064-1 1998 We conducted a 3-year randomized placebo-controlled double-blind study to determine the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril (PE) on the progress of renal function and histology in subjects with diabetes and microalbuminuria. Perindopril 162-164 angiotensin I converting enzyme Homo sapiens 103-132 9867064-1 1998 We conducted a 3-year randomized placebo-controlled double-blind study to determine the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril (PE) on the progress of renal function and histology in subjects with diabetes and microalbuminuria. Perindopril 162-164 angiotensin I converting enzyme Homo sapiens 134-137 9867066-5 1998 Clinical studies have now confirmed these findings, showing that when previously untreated essential hypertensive patients are treated with the ACE inhibitor perindopril (PE), the abnormal structure of resistance vessels regresses toward normal values; in contrast, treatment with a beta-blocker does not affect the abnormal vascular structure. Perindopril 158-169 angiotensin I converting enzyme Homo sapiens 144-147 9867066-5 1998 Clinical studies have now confirmed these findings, showing that when previously untreated essential hypertensive patients are treated with the ACE inhibitor perindopril (PE), the abnormal structure of resistance vessels regresses toward normal values; in contrast, treatment with a beta-blocker does not affect the abnormal vascular structure. Perindopril 171-173 angiotensin I converting enzyme Homo sapiens 144-147 9781930-1 1998 The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients. Perindopril 102-113 angiotensin I converting enzyme Homo sapiens 87-90 9796841-3 1998 OBJECTIVE: The objective of EUROPA is to assess the effects of perindopril (an ACE inhibitor) on outcome in patients with stable coronary artery disease, but no clinical heart failure. Perindopril 63-74 angiotensin I converting enzyme Homo sapiens 79-82 9783492-14 1998 ACE therapy with perindopril is well tolerated in the studied population. Perindopril 17-28 angiotensin I converting enzyme Homo sapiens 0-3 16793747-0 1998 Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Perindopril 61-72 angiotensin I converting enzyme Homo sapiens 46-49 9504354-5 1998 The addition of perindopril to amlodipine decreased serum ACE by 72% and increased PRA two-fold, without change in plasma levels of Ang II, aldosterone or alpha-h ANP. Perindopril 16-27 angiotensin I converting enzyme Homo sapiens 58-61 9540129-4 1998 Several studies in hypertensive patients have now shown that treatment with some ACE inhibitors (cilazapril and perindopril) or extended release calcium channel antagonists (nifedipine GITS) induces similar effects in small arteries obtained from gluteal subcutaneous biopsies: both structure and endothelium-dependent relaxation improve under treatment. Perindopril 112-123 angiotensin I converting enzyme Homo sapiens 81-84 9634724-5 1998 The treatment with ACE inhibitor during 3 months (4 mg of Perindopril per day) decreased ACE activity in patients" plasma which was accompanied with decreasing of the arterial pressure and some restoration of the carbohydrate metabolism indicators. Perindopril 58-69 angiotensin I converting enzyme Homo sapiens 19-22 9634724-5 1998 The treatment with ACE inhibitor during 3 months (4 mg of Perindopril per day) decreased ACE activity in patients" plasma which was accompanied with decreasing of the arterial pressure and some restoration of the carbohydrate metabolism indicators. Perindopril 58-69 angiotensin I converting enzyme Homo sapiens 89-92 9634724-6 1998 The hyperinsulinemic euglycaemic clamping of 7 patients with NIDDM and essential hypertension showed that ACE-inhibitor (Perindopril, 4 mg) prevented bradykinin from destruction and increased the glucose consumption by tissues. Perindopril 121-132 angiotensin I converting enzyme Homo sapiens 106-109 9241099-1 1997 AIMS: Previous studies in heart failure (CHF) after temporary diuretic withdrawal have suggested that perindopril is associated with no first dose hypotension in comparison with other ACE inhibitors (ACEI) or placebo. Perindopril 102-113 angiotensin I converting enzyme Homo sapiens 184-187 9236432-2 1997 The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease. Perindopril 106-117 angiotensin I converting enzyme Homo sapiens 89-92 9236432-5 1997 The patients treated with perindopril had lower plasma ACE (P < .001) and plasma angiotensin (Ang) II-to-Ang I ratio (P < .05). Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 55-58 9236432-6 1997 In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001). Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 37-40 9236432-8 1997 Light microscopic autoradiographs of 125I-351A binding revealed a marked inhibition of ACE by perindopril in both layers of the vascular wall. Perindopril 94-105 angiotensin I converting enzyme Homo sapiens 87-90 9236432-9 1997 CONCLUSIONS: The present demonstrates that long-term administration of perindopril potently inhibits both endothelial and adventitial ACE to a comparable degree in the human internal mammary artery. Perindopril 71-82 angiotensin I converting enzyme Homo sapiens 134-137 9236432-10 1997 These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall. Perindopril 28-39 angiotensin I converting enzyme Homo sapiens 92-95 9236432-10 1997 These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall. Perindopril 144-155 angiotensin I converting enzyme Homo sapiens 92-95 9402466-5 1997 However, when titrated in clinical practice on post-dose (peak) blood pressure response, doses are used that are inadequate to control blood pressure for 24 h. ACE inhibitors with appropriate pharmacokinetics such as perindopril can control blood pressure when titrated at peak provided a dose is used (4 or 8 mg) that is known to have a T:P close to 1.0. Perindopril 217-228 angiotensin I converting enzyme Homo sapiens 160-163 9340173-4 1997 The PROGRESS ("Perindopril Protection Against Recurrent Stroke Study") study has been designed and is under way to collect information on this important issue of the antihypertensive treatment, its purpose being to evaluate the blood pressure lowering effects with an ACE-inhibitor on recurrent stroke in an overall population of 6000 patients with a positive history of previous cerebral ischemic attacks or stroke. Perindopril 15-26 angiotensin I converting enzyme Homo sapiens 268-271 9247754-7 1997 Preliminary results from the Melbourne Diabetic Nephropathy Study Group suggest that the ACE inhibitor, perindopril, is more effective than the dihydropyridine calcium channel blocker, nifedipine, in retarding the rise in urinary albumin excretion in normotensive insulin and noninsulin dependent diabetic patients with microalbuminuria. Perindopril 104-115 angiotensin I converting enzyme Homo sapiens 89-92 9241099-3 1997 METHODS: We report the effects of acute and chronic (8 weeks) treatment with the ACE inhibitor perindopril (Per, 2-->4 mg daily) or placebo (P) in a double-blind parallel group study of 24 diuretic treated patients (17M; 67 +/- 8 years, 80 +/- 17 kg) with ischaemic cardiomyopathy (fractional shortening, 19 +/- 5%; radionuclide ejection fraction, 31 +/- 3%). Perindopril 95-106 angiotensin I converting enzyme Homo sapiens 81-84 7484889-8 1995 Recent data suggest that ACE inhibitors such as perindopril improve distensibility and compliance of large arteries more than diuretics such as amiloride/hydrochlorothiazide. Perindopril 48-59 angiotensin I converting enzyme Homo sapiens 25-28 9056614-4 1997 We tested the hypothesis that perindopril, an angiotensin-converting enzyme inhibitor with a gradual onset of action and a minimal first-dose hypotensive effect, lowers blood pressure without adversely affecting cerebral blood flow in patients 2 to 7 days after symptoms of cerebral infarction. Perindopril 30-41 angiotensin I converting enzyme Homo sapiens 46-75 8713688-4 1996 PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a multicentre, randomized, placebo-controlled trial that aims to determine reliably the effect of angiotensin converting enzyme (ACE) inhibitor-based blood pressure lowering on stroke risk in patients with a history of cerebrovascular disease. Perindopril 10-21 angiotensin I converting enzyme Homo sapiens 166-195 8713688-4 1996 PROGRESS (Perindopril Protection Against Recurrent Stroke Study) is a multicentre, randomized, placebo-controlled trial that aims to determine reliably the effect of angiotensin converting enzyme (ACE) inhibitor-based blood pressure lowering on stroke risk in patients with a history of cerebrovascular disease. Perindopril 10-21 angiotensin I converting enzyme Homo sapiens 197-200 9426847-0 1997 Effect of angiotensin converting enzyme inhibition by perindopril on proteinuria of primary renal diseases. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 10-39 9426847-3 1997 We conducted a double-blind, parallel-design, placebo-controlled study of 1 year duration to evaluate the efficacy of the new ACE inhibitor, perindopril, in reducing proteinuria in patients with nephrotic syndrome due to histologically proven membranous and membranoproliferative glomerulonephritis and focal segmental glomerulosclerosis. Perindopril 141-152 angiotensin I converting enzyme Homo sapiens 126-129 9503533-0 1997 [Change of circadian pattern of arterial pressure in patients with congestive heart failure treated with perindopril, an inhibitor of angiotensin-converting enzyme (ACE)]. Perindopril 105-116 angiotensin I converting enzyme Homo sapiens 134-163 9503533-0 1997 [Change of circadian pattern of arterial pressure in patients with congestive heart failure treated with perindopril, an inhibitor of angiotensin-converting enzyme (ACE)]. Perindopril 105-116 angiotensin I converting enzyme Homo sapiens 165-168 9023709-10 1996 The ACE inhibitor perindopril has been compared not only with placebo but also with the dihydropyridine calcium channel blocker, nifedipine. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 4-7 9023711-7 1996 Clinical studies have now confirmed these findings, showing that when previously untreated essential hypertensive patients are treated with the ACE inhibitor perindopril the abnormal structure of resistance vessels regresses towards normal values; in contrast, treatment with a beta-blocker does not affect the abnormal vascular structure. Perindopril 158-169 angiotensin I converting enzyme Homo sapiens 144-147 9023714-3 1996 This study uses angiotensin-converting enzyme (ACE) inhibitor-based treatment (perindopril) versus placebo. Perindopril 79-90 angiotensin I converting enzyme Homo sapiens 16-45 9023714-3 1996 This study uses angiotensin-converting enzyme (ACE) inhibitor-based treatment (perindopril) versus placebo. Perindopril 79-90 angiotensin I converting enzyme Homo sapiens 47-50 8761842-8 1996 Therefore, the ACE inhibitor perindopril is neutral with regard to insulin sensitivity, plasma insulin and glucose, and lipoprotein metabolism in overweight, nondiabetic patients with essential hypertension. Perindopril 29-40 angiotensin I converting enzyme Homo sapiens 15-18 8738072-2 1996 They followed an unrestricted diet and received a single oral daily dose of 4 mg perindopril (ACE inhibitor) for 6 weeks. Perindopril 81-92 angiotensin I converting enzyme Homo sapiens 94-97 7484889-10 1995 ACE inhibitors such as perindopril decrease the afterload on the heart more than diuretics such as amiloride/hydrochlorothiazide by both a more pronounced decrease in systemic vascular resistance and an increase in large artery compliance. Perindopril 23-34 angiotensin I converting enzyme Homo sapiens 0-3 7484890-5 1995 Therefore, a multicenter, randomized, double-blind European trial was designed to compare the effects of the ACE inhibitor perindopril and the diuretic hydrochlorothiazide in slowing or reversing progression of increased intima/media thickness of carotid and femoral arteries in hypertensive patients. Perindopril 123-134 angiotensin I converting enzyme Homo sapiens 109-112 8557961-1 1995 OBJECTIVE: To compare the cardiovascular effects of 6 months of treatment with the angiotensin converting enzyme inhibitor perindopril and with the diuretic combination amiloride+hydrochlorothiazide, and to study possible persistence of observed treatment effects after discontinuation of antihypertensive therapy. Perindopril 123-134 angiotensin I converting enzyme Homo sapiens 83-112 7649594-7 1995 Studies on local distensibility and compliance revealed that with the calcium antagonist verapamil and the angiotensin-converting enzyme inhibitor perindopril arterial compliance increased mainly because of an increase in distensibility, with only a minor effect on arterial diameter. Perindopril 147-158 angiotensin I converting enzyme Homo sapiens 107-136 7571476-0 1995 [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. Perindopril 40-51 angiotensin I converting enzyme Homo sapiens 69-72 7496564-0 1995 Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Perindopril 127-138 angiotensin I converting enzyme Homo sapiens 113-116 7571476-2 1995 This one-year open study conducted in two centres investigated the 24-hour effectiveness of the ACE inhibitor perindopril in the treatment of 31 patients with mild or moderate hypertension. Perindopril 110-121 angiotensin I converting enzyme Homo sapiens 96-99 7596136-3 1995 We investigated whether long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor perindopril can improve endothelium-dependent vasodilation in this particular group of patients. Perindopril 99-110 angiotensin I converting enzyme Homo sapiens 53-82 7614778-15 1995 Individual ACE inhibitors are affected differently, but importantly the dosage of perindopril should be reduced in patients with CHF, while for most other ACE inhibitors the changes in pharmacokinetic parameters are clinically irrelevant. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 11-14 7596136-3 1995 We investigated whether long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor perindopril can improve endothelium-dependent vasodilation in this particular group of patients. Perindopril 99-110 angiotensin I converting enzyme Homo sapiens 84-87 8059778-0 1994 ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 7566576-5 1995 Patients were randomly allocated to receive either placebo or the ACE inhibitor perindopril (2 mg/day per os) for 14 days. Perindopril 80-91 angiotensin I converting enzyme Homo sapiens 66-69 7954033-4 1994 Perindopril is a third generation converting enzyme inhibitor that produces profound and prolonged angiotensin-converting enzyme (ACE) inhibition (24 h after a single dose). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 99-128 7954033-4 1994 Perindopril is a third generation converting enzyme inhibitor that produces profound and prolonged angiotensin-converting enzyme (ACE) inhibition (24 h after a single dose). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 130-133 7954036-7 1994 The new ACE inhibitor perindopril differs from most others in terms of BVW protection. Perindopril 22-33 angiotensin I converting enzyme Homo sapiens 8-11 7954040-7 1994 Recent data suggest that ACE inhibitors like perindopril improve distensibility and compliance of large arteries more than diuretics such as amiloride hydrochlorothiazide do. Perindopril 45-56 angiotensin I converting enzyme Homo sapiens 25-28 7954040-9 1994 ACE inhibitors like perindopril decrease the afterload on the heart more than diuretics (such as amiloride hydrochlorothiazide) by both a more pronounced decrease in systemic vascular resistance and increase in large artery compliance. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 7954041-2 1994 The efficacy and acceptability of the angiotensin-converting enzyme (ACE) inhibitor perindopril were compared with those of an established treatment for hypertension in Canada, slow release diltiazem. Perindopril 84-95 angiotensin I converting enzyme Homo sapiens 69-72 7697693-1 1994 This study assessed the effects of an angiotensin-converting enzyme (ACE) inhibitor, perindopril, on the 24-hour blood pressure (BP) profile and hemodynamic responses to isometric exercise and mental stress in elderly hypertensive patients. Perindopril 85-96 angiotensin I converting enzyme Homo sapiens 38-67 7697693-1 1994 This study assessed the effects of an angiotensin-converting enzyme (ACE) inhibitor, perindopril, on the 24-hour blood pressure (BP) profile and hemodynamic responses to isometric exercise and mental stress in elderly hypertensive patients. Perindopril 85-96 angiotensin I converting enzyme Homo sapiens 69-72 11835076-1 1994 This study evaluated the efficacy and tolerability of perindopril erbumine, a long-acting ACE inhibitor, added to continuing hydrochlorothiazide (HCTZ) therapy in hypertensive patients (DBP of 95 to 114 mmHg) whose blood pressure did not normalize (supine DBP <90 mmHg) with HCTZ therapy alone. Perindopril 54-74 angiotensin I converting enzyme Homo sapiens 90-93 8059778-4 1994 In the present study, the possible interactions of the ACE-inhibitor perindopril with several of the most common long-term diseases was evaluated. Perindopril 69-80 angiotensin I converting enzyme Homo sapiens 55-58 8059778-11 1994 CONCLUSION: This trial shows that ACE-inhibition with perindopril represents a simple, safe, and effective short-term therapeutic option for the large proportion of patients with mild essential hypertension and concomitant diseases and therapies. Perindopril 54-65 angiotensin I converting enzyme Homo sapiens 34-37 7523776-2 1994 To evaluate the effects of the novel angiotensin-converting enzyme (ACE) inhibitor, perindopril on these exercise-related responses, we studied 9 healthy volunteers in a double-blind, randomized, placebo-controlled trial. Perindopril 84-95 angiotensin I converting enzyme Homo sapiens 68-71 1657092-1 1991 1 Perindopril is a prodrug which is hydrolysed in vivo to the active metabolite perindoprilat, an angiotensin-converting enzyme inhibitor. Perindopril 2-13 angiotensin I converting enzyme Homo sapiens 98-127 7516014-1 1994 The effect of the angiotensin-converting enzyme (ACE)-inhibitor perindopril on serum lipids and apolipoprotein concentrations were assessed in a multicenter, randomized, double-blind, placebo-controlled study in 51 hyperlipidemic patients treated for mild hypertension. Perindopril 64-75 angiotensin I converting enzyme Homo sapiens 49-52 8216441-10 1993 From this study it can be concluded that in hypertension with concomitant nephropathy, except renovascular hypertension and hypertension in renal transplant recipients, ACE inhibition by perindopril will not impair kidney function. Perindopril 187-198 angiotensin I converting enzyme Homo sapiens 169-172 1279299-6 1992 Perindopril also produced a prolonged dose-dependent inhibition of plasma angiotensin-converting enzyme (ACE) activity that was maximum after 4 h and had not fully recovered by 48 h after a single dose. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 74-103 1279299-6 1992 Perindopril also produced a prolonged dose-dependent inhibition of plasma angiotensin-converting enzyme (ACE) activity that was maximum after 4 h and had not fully recovered by 48 h after a single dose. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 105-108 1576057-1 1992 Perindopril is a non-sulphydryl angiotensin converting enzyme (ACE) inhibitor which requires hydrolysis to its active metabolite, perindoprilat, to produce its effects. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 63-66 1925812-0 1991 Perindopril (Coversyl)--a new ACE inhibitor. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 30-33 1651180-4 1991 During perindopril therapy, changes in the ratio of ANG II:ANG I, an index of ACE activity in vivo, showed a close agreement with changes in plasma ACE activity measured with FAPGG as substrate, but not with HHL as substrate. Perindopril 7-18 angiotensin I converting enzyme Homo sapiens 78-81 1651180-4 1991 During perindopril therapy, changes in the ratio of ANG II:ANG I, an index of ACE activity in vivo, showed a close agreement with changes in plasma ACE activity measured with FAPGG as substrate, but not with HHL as substrate. Perindopril 7-18 angiotensin I converting enzyme Homo sapiens 148-151 8216441-8 1993 In a subgroup of patients with isolated albuminuria ACE inhibition reduced significantly the urinary albumin excretion (perindopril: -292 +/- 205 mg/g creat. Perindopril 120-131 angiotensin I converting enzyme Homo sapiens 52-55 8328364-1 1993 The antihypertensive efficacy and acceptability of perindopril, an angiotensin-converting enzyme (ACE) inhibitor, was evaluated in 2,927 elderly (> or = 70 years) hypertensive patients in general practice, as part of an open 6-month trial conducted on a total of 23,460 patients with mild-to-moderate hypertension. Perindopril 51-62 angiotensin I converting enzyme Homo sapiens 98-101 1329465-5 1992 In contrast, drugs requiring biotransformation to active forms, e.g., angiotensin-converting enzyme (ACE) inhibitors such as enalapril, perindopril, quinapril, and ramipril, generally have lower than expected plasma concentrations. Perindopril 136-147 angiotensin I converting enzyme Homo sapiens 70-99 1329465-5 1992 In contrast, drugs requiring biotransformation to active forms, e.g., angiotensin-converting enzyme (ACE) inhibitors such as enalapril, perindopril, quinapril, and ramipril, generally have lower than expected plasma concentrations. Perindopril 136-147 angiotensin I converting enzyme Homo sapiens 101-104 1330941-0 1992 Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE. Perindopril 38-49 angiotensin I converting enzyme Homo sapiens 85-88 1580274-0 1992 Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Perindopril 101-112 angiotensin I converting enzyme Homo sapiens 57-86 1580274-1 1992 We studied the long-term effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril, administered for 36 months on glycemic control, creatinine clearance, and albuminuria in hypertensive insulin-treated diabetics. Perindopril 86-97 angiotensin I converting enzyme Homo sapiens 71-74 1580277-5 1992 Once the renin component of hypertension is established, management with angiotensin-converting enzyme (ACE) inhibitors, such as perindopril, follows, for ACE inhibitors attack the pathophysiologic source, thus providing adequate perfusion and protection of vital organs. Perindopril 129-140 angiotensin I converting enzyme Homo sapiens 73-102 1580277-5 1992 Once the renin component of hypertension is established, management with angiotensin-converting enzyme (ACE) inhibitors, such as perindopril, follows, for ACE inhibitors attack the pathophysiologic source, thus providing adequate perfusion and protection of vital organs. Perindopril 129-140 angiotensin I converting enzyme Homo sapiens 104-107 1580282-1 1992 The excretions of urinary sodium, potassium, magnesium, urate, and water after dosing with diuretics or the angiotensin-converting enzyme inhibitor perindopril are reported, as well as the results of other recent studies. Perindopril 148-159 angiotensin I converting enzyme Homo sapiens 108-137 1580283-3 1992 The present study was designed to elucidate whether treatment with perindopril (a new angiotensin-converting enzyme [ACE] inhibitor) affects plasma lipid metabolism, glucose homeostasis, and insulin sensitivity. Perindopril 67-78 angiotensin I converting enzyme Homo sapiens 86-115 1580283-3 1992 The present study was designed to elucidate whether treatment with perindopril (a new angiotensin-converting enzyme [ACE] inhibitor) affects plasma lipid metabolism, glucose homeostasis, and insulin sensitivity. Perindopril 67-78 angiotensin I converting enzyme Homo sapiens 117-120 1580284-1 1992 A 3-month double-blind multicenter trial compared the efficacy and safety of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor, with atenolol in mild-to-moderate essential hypertension. Perindopril 77-88 angiotensin I converting enzyme Homo sapiens 127-130 1580288-1 1992 This study is aimed at assessing long-term efficacy and tolerance of a newly developed angiotensin-converting-enzyme (ACE) inhibitor, perindopril, in type II diabetics. Perindopril 134-145 angiotensin I converting enzyme Homo sapiens 87-116 1580288-1 1992 This study is aimed at assessing long-term efficacy and tolerance of a newly developed angiotensin-converting-enzyme (ACE) inhibitor, perindopril, in type II diabetics. Perindopril 134-145 angiotensin I converting enzyme Homo sapiens 118-121 1580290-0 1992 Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study. Perindopril 169-180 angiotensin I converting enzyme Homo sapiens 0-29 1580290-4 1992 This possibility has been addressed in an ongoing trial of novel design, the Perindopril Therapeutic Safety Study, a multicenter, double-blind, randomized and placebo-controlled trial to determine the safety, efficacy, and interaction of angiotensin-converting enzyme (ACE) inhibition with eight of the most common concomitant diseases and their therapies. Perindopril 77-88 angiotensin I converting enzyme Homo sapiens 238-267 1327597-4 1992 Following acute administration of lisinopril, perindopril or benazepril, ACE was markedly inhibited in the lung, kidney and blood vessels but not in the testis. Perindopril 46-57 angiotensin I converting enzyme Homo sapiens 73-76 1327597-7 1992 High doses of perindopril progressively inhibited ACE in other brain structures. Perindopril 14-25 angiotensin I converting enzyme Homo sapiens 50-53 1327597-9 1992 In the case of perindopril, the time course of tissue ACE inhibition correlated with the inhibition of the pressor responses to exogenous angiotensin I. Perindopril 15-26 angiotensin I converting enzyme Homo sapiens 54-57 1327597-11 1992 After chronic administration of lisinopril or perindopril for 14 days, a similar pattern of ACE inhibition was observed in the kidney, lung and blood vessels. Perindopril 46-57 angiotensin I converting enzyme Homo sapiens 92-95 1327597-12 1992 In the lung, however, lisinopril was found to increase total ACE by 30%, while plasma ACE was increased two-threefold by both lisinopril and perindopril. Perindopril 141-152 angiotensin I converting enzyme Homo sapiens 86-89 1657084-13 1991 Though perindopril produced a similar plasma ACE inhibition to that produced by enalapril, it only caused changes in blood pressure that were similar to those caused by placebo. Perindopril 7-18 angiotensin I converting enzyme Homo sapiens 45-48 1657084-14 1991 CONCLUSIONS: This controlled study is the first to indicate a qualitative difference in the acute response to angiotensin converting enzyme inhibitors with similar structure and metabolism (that is, enalapril and perindopril). Perindopril 213-224 angiotensin I converting enzyme Homo sapiens 110-139 1718688-2 1991 Perindopril is a long acting angiotensin converting enzyme (ACE) inhibitor, which displays similar pharmacodynamic properties to other agents in this class. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 29-58 1718688-2 1991 Perindopril is a long acting angiotensin converting enzyme (ACE) inhibitor, which displays similar pharmacodynamic properties to other agents in this class. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 60-63 1718688-4 1991 After absorption, perindopril is hydrolysed to the active metabolite, perindoprilat, and with once daily administration adequate 24-hour inhibition of ACE is obtained. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 151-154 1875747-0 1991 [International experts commented on the characteristics of perindopril, a new highly potent and well tolerated ACE. Perindopril 59-70 angiotensin I converting enzyme Homo sapiens 111-114 2051826-1 1991 Presentation of perindopril, a new and potent ACE inhibitor. Perindopril 16-27 angiotensin I converting enzyme Homo sapiens 46-49 1834452-0 1991 More ACE inhibitors--quinapril, perindopril & ramipril. Perindopril 32-43 angiotensin I converting enzyme Homo sapiens 5-8 2051826-2 1991 Perindopril exerts an efficacious and rapid inhibition of ACE in plasma as well as in tissues]. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 58-61 2351367-1 1990 Perindopril, an angiotensin converting enzyme (ACE) inhibitor, is converted in vivo to its active diacid metabolite, perindoprilat and to a perindoprilat glucuronide. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 16-45 1682228-1 1991 The aim of this 3-month double-blind multicenter trial was to compare the antihypertensive efficacy and tolerability of the ACE inhibitor perindopril with those of a diuretic combination. Perindopril 138-149 angiotensin I converting enzyme Homo sapiens 124-127 1725197-4 1991 Based on these data, the effects of perindopril, a potent and long-lasting angiotensin-converting enzyme (ACE) inhibitor, on structural and mechanical properties of the arterial wall, have been studied in animal models of hypertension as well as in humans. Perindopril 36-47 angiotensin I converting enzyme Homo sapiens 75-104 1725198-1 1991 To evaluate whether perindopril, a carboxyl-containing new angiotensin-converting enzyme (ACE) inhibitor, exerts its antihypertensive action through the stimulation of prostaglandin synthesis, 10 uncomplicated essential hypertensive patients randomly received indomethacin (50 mg b.i.d.) Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 59-88 1725198-1 1991 To evaluate whether perindopril, a carboxyl-containing new angiotensin-converting enzyme (ACE) inhibitor, exerts its antihypertensive action through the stimulation of prostaglandin synthesis, 10 uncomplicated essential hypertensive patients randomly received indomethacin (50 mg b.i.d.) Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 90-93 1725198-3 1991 Perindopril alone tended to reduce serum and urinary thromboxane B2 (TxB2) and to raise urinary 6-ketoPGF1 alpha and PGE2 and inhibited serum ACE activity 24 h post dosing by about 85%. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 142-145 1817672-0 1991 A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. Perindopril 92-103 angiotensin I converting enzyme Homo sapiens 52-81 1817672-1 1991 A new radioimmunoassay (RIA) was developed for the direct measurement of perindoprilate (PT), the active metabolite (diacid) of Perindopril (P), an angiotensin-converting enzyme (ACE) inhibitor. Perindopril 128-139 angiotensin I converting enzyme Homo sapiens 148-177 2283644-1 1990 A multicentre randomised double-blind trial was performed in order to compare the therapeutic efficacy and acceptability of the angiotensin converting enzyme (ACE) inhibitor perindopril with those of atenolol in mild to moderate hypertension. Perindopril 174-185 angiotensin I converting enzyme Homo sapiens 159-162 2283650-4 1990 The effects of monotherapy with the ACE inhibitor perindopril (8 mg once daily) on 24 hour ambulatory intra-arterial BP demonstrated that after six weeks" treatment there is a significant reduction in ambulatory BP, as compared with the placebo period, without any associated reflex tachycardia. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 36-39 2283652-1 1990 Blood pressure, forearm arterial haemodynamics and echocardiographic parameters were studied in patients with sustained essential hypertension before and after administration of the ACE inhibitor, perindopril. Perindopril 197-208 angiotensin I converting enzyme Homo sapiens 182-185 2283658-1 1990 Perindopril is a non-sulphydryl, pro-drug, ACE inhibitor. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 43-46 2283658-4 1990 Inhibition of ACE is dose-dependent over the range 1-16 mg perindopril orally, and is mirrored by elevation of plasma renin activity and falls in aldosterone concentrations. Perindopril 59-70 angiotensin I converting enzyme Homo sapiens 14-17 2226219-9 1990 Many new ACE inhibitors are undergoing clinical assessment, including alacepril, cilazapril, fosenopril, perindopril, quinapril and ramipril. Perindopril 105-116 angiotensin I converting enzyme Homo sapiens 9-12 2231339-0 1990 Radioimmunoassay of a new angiotensin-converting enzyme inhibitor (perindopril) in human plasma and urine: advantages of coupling anion-exchange column chromatography with radioimmunoassay. Perindopril 67-78 angiotensin I converting enzyme Homo sapiens 26-55 2231339-1 1990 Perindopril (P) is a prodrug whose active metabolite perindoprilat (PT) is an antihypertensive agent which acts by inhibition of angiotensin-converting enzyme (ACE). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 129-158 2231339-1 1990 Perindopril (P) is a prodrug whose active metabolite perindoprilat (PT) is an antihypertensive agent which acts by inhibition of angiotensin-converting enzyme (ACE). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 160-163 1691380-1 1990 The acute systemic and regional hemodynamic responses to a single oral dose (4 mg) of the angiotensin converting enzyme inhibitor perindopril were investigated in 10 patients with severe congestive heart failure. Perindopril 130-141 angiotensin I converting enzyme Homo sapiens 90-119 2407492-1 1990 Perindopril is an orally active non-thiol angiotensin-converting enzyme (ACE) inhibitor that is hydrolysed by esterases to a biologically active diacid metabolite. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 42-71 2407492-1 1990 Perindopril is an orally active non-thiol angiotensin-converting enzyme (ACE) inhibitor that is hydrolysed by esterases to a biologically active diacid metabolite. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 73-76 2407492-3 1990 Most data support the hypothesis that the beneficial haemodynamic effects of perindopril are caused by ACE inhibition and the consequent reduction in angiotensin II, which either directly or indirectly results in dilatation of peripheral vessels and reduced vascular resistance. Perindopril 77-88 angiotensin I converting enzyme Homo sapiens 103-106 2407493-2 1990 Perindopril is an orally active, non-thiol angiotensin-converting enzyme (ACE) inhibitor, which in doses of 4 to 8mg is effective in the control of essential hypertension. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 43-72 2407493-2 1990 Perindopril is an orally active, non-thiol angiotensin-converting enzyme (ACE) inhibitor, which in doses of 4 to 8mg is effective in the control of essential hypertension. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 74-77 2407493-6 1990 Perindopril is a prodrug which requires de-esterification to perindoprilat for useful ACE inhibition. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 86-89 2407494-3 1990 Perindopril, a new ACE inhibitor, is well tolerated and associated with fewer side effects than other types of antihypertensive agents. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 19-22 2281920-1 1990 We studied the effects of perindopril, an angiotensin converting enzyme (ACE) inhibitor administered during 12 months, on creatinine clearance, albuminuria and glycaemic control in diabetic subjects with mild to moderate hypertension. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 73-76 2219962-0 1990 Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor. Perindopril 53-64 angiotensin I converting enzyme Homo sapiens 72-101 2219962-0 1990 Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor. Perindopril 53-64 angiotensin I converting enzyme Homo sapiens 103-106 2219962-2 1990 The metabolism of perindopril (non-thiol angiotensin-converting enzyme inhibitor) was studied in rat, dog and monkey after single oral and i.v. Perindopril 18-29 angiotensin I converting enzyme Homo sapiens 41-70 2311339-2 1990 Perindopril is the ester pro-drug of the angiotensin-converting enzyme inhibitor perindoprilat. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 41-70 2185055-0 1990 Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Perindopril 100-111 angiotensin I converting enzyme Homo sapiens 56-85 2185055-1 1990 We studied the effects of perindopril, an angiotensin converting enzyme (ACE) inhibitor administered during 12 months, on creatinine clearance, albuminuria and glycaemic control in diabetic subjects with mild to moderate hypertension. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 73-76 2351367-1 1990 Perindopril, an angiotensin converting enzyme (ACE) inhibitor, is converted in vivo to its active diacid metabolite, perindoprilat and to a perindoprilat glucuronide. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 47-50 34074111-5 2021 Morbidity mortality studies of RAAS blockers have been reported in which ACE inhibitors, particularly perindopril, improved the overall survival in hypertensive patients. Perindopril 102-113 angiotensin I converting enzyme Homo sapiens 73-76 34614428-6 2021 METHODS: There were 48 treatment-naive hypertensive patients who were diagnosed according to the "2013 European Society of Hypertension/European Society of Cardiology" guideline and started angiotensin-converting enzyme inhibitor perindopril (Coversyl) in the study. Perindopril 230-241 angiotensin I converting enzyme Homo sapiens 190-219 34248634-5 2021 We found that the expressions of AT1R, AT2R and ACE in the interface membrane from patients with PPOL and in calvarial tissues from a murine model of Ti-particle-induced osteolysis were up-regulated, but the increase of ACE in the calvarial tissues was abrogated by perindopril. Perindopril 266-277 angiotensin I converting enzyme Homo sapiens 48-51 31578675-0 2019 A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril. Perindopril 137-148 angiotensin I converting enzyme Homo sapiens 86-115 31578675-7 2019 Among the ACE inhibitors, perindopril appears to have the greatest effects on bradykinin and has demonstrated efficacy in a number of markers of endothelial dysfunction including arterial stiffness and progression of atherosclerosis. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 10-13 34616396-6 2021 Treating the cells with an ACE inhibitor, perindopril, at 100 microM reduced apoptosis, ROS, and MHC-II expression induced by S protein. Perindopril 42-53 angiotensin I converting enzyme Homo sapiens 27-30 33186235-3 2021 The angiotensin-converting enzyme (ACE)-inhibitor perindopril improves myocardial blood flow (MBF) in animal models of cardiac hypertrophy and in hypertensive patients. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 4-33 33186235-3 2021 The angiotensin-converting enzyme (ACE)-inhibitor perindopril improves myocardial blood flow (MBF) in animal models of cardiac hypertrophy and in hypertensive patients. Perindopril 50-61 angiotensin I converting enzyme Homo sapiens 35-38 34074111-7 2021 Perindopril, which has been used in the clinical practice for more than 25 years, is a long-acting lipophilic angiotensin-converting enzyme inhibitor with a once-daily dosage schedule and a high affinity to tissue-converting enzyme. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 110-139 2553899-7 1989 Perindopril crossed the blood-brain barrier and inhibited brain ACE at high doses, but after equivalent doses of quinapril no brain ACE inhibition could be demonstrated. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 64-67 35082055-4 2022 CONCLUSION: Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications. Perindopril 91-102 angiotensin I converting enzyme Homo sapiens 45-48 2505717-9 1989 In a trial performed on healthy volunteers, Reid found that perindopril had a greater effect of arterial pressure in elderly subjects, probably due in part to their high blood pressure and to an earlier and more prolonged inhibition of the angiotensin-converting enzyme (NS). Perindopril 60-71 angiotensin I converting enzyme Homo sapiens 240-269 2550045-2 1989 Perindopril, a new ACE inhibitor, is a prodrug requiring conversion into its active form perindoprilat by hydrolysis in the liver. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 19-22 2549899-1 1989 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril was evaluated in normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 22-51 2549899-1 1989 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril was evaluated in normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 53-56 2549899-8 1989 ACE inhibition with perindopril did not affect blood pressure and heart rate in any consistent manner. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 2549899-11 1989 The long-acting ACE inhibitor perindopril appears therefore to be effective when given orally in a dose range of 4 to 16 mg. Perindopril 30-41 angiotensin I converting enzyme Homo sapiens 16-19 2605800-1 1989 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril was evaluated in normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 22-51 2691127-4 1989 Angiotensin converting enzyme (ACE) inhibitors such as perindopril not only reduce high blood pressure, but also increase arterial compliance and distensibility. Perindopril 55-66 angiotensin I converting enzyme Homo sapiens 0-29 2691127-4 1989 Angiotensin converting enzyme (ACE) inhibitors such as perindopril not only reduce high blood pressure, but also increase arterial compliance and distensibility. Perindopril 55-66 angiotensin I converting enzyme Homo sapiens 31-34 2691131-0 1989 Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril. Perindopril 81-92 angiotensin I converting enzyme Homo sapiens 9-38 2605800-1 1989 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril was evaluated in normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 53-56 2605800-8 1989 ACE inhibition with perindopril did not consistently affect blood pressure and heart rate. Perindopril 20-31 angiotensin I converting enzyme Homo sapiens 0-3 2605800-11 1989 The long-acting ACE inhibitor perindopril therefore appears to be effective when given orally in a dose range of 4 to 16 mg. Perindopril 30-41 angiotensin I converting enzyme Homo sapiens 16-19 2844467-1 1988 Perindopril is the ester prodrug of the angiotensin converting enzyme inhibitor S-9780. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 40-69 3225692-1 1988 Non-invasive ambulatory blood pressure monitoring (Spacelabs 5200) was carried out before and 3 months after treatment with perindopril, a new angiotensin converting enzyme (ACE) inhibitor given at 4-8 mg once a day in the morning. Perindopril 124-135 angiotensin I converting enzyme Homo sapiens 143-172 3225692-1 1988 Non-invasive ambulatory blood pressure monitoring (Spacelabs 5200) was carried out before and 3 months after treatment with perindopril, a new angiotensin converting enzyme (ACE) inhibitor given at 4-8 mg once a day in the morning. Perindopril 124-135 angiotensin I converting enzyme Homo sapiens 174-177 3038395-0 1987 Perindopril, a new angiotensin converting enzyme inhibitor--clinical pharmacological studies in healthy subjects. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 19-48 2441162-1 1987 S-9780 is the active diacid metabolite of the new angiotensin-converting enzyme (ACE) inhibitor perindopril. Perindopril 96-107 angiotensin I converting enzyme Homo sapiens 81-84 3038395-2 1987 Oral administration of perindopril (1-16 mg) to groups of 6 healthy males led to a long lasting and dose-elated inhibition of plasma ACE and rises in plasma renin activity with no evidence of accumulation of drug or effect. Perindopril 23-34 angiotensin I converting enzyme Homo sapiens 133-136 3038395-1 1987 Perindopril is a new angiotensin converting enzyme (ACE) inhibitor which is activated after hydrolysis in vivo to a diacid (S9780). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 21-50 3038395-1 1987 Perindopril is a new angiotensin converting enzyme (ACE) inhibitor which is activated after hydrolysis in vivo to a diacid (S9780). Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 52-55 33553408-11 2021 The patient was treated with an angiotensin-converting-enzyme inhibitor (perindopril) and a beta-blocker (metoprolol). Perindopril 73-84 angiotensin I converting enzyme Homo sapiens 32-61 3516512-1 1986 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril (S9490-3) was evaluated in 18 normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 22-51 3516512-1 1986 The new orally active angiotensin converting enzyme (ACE) inhibitor perindopril (S9490-3) was evaluated in 18 normotensive men. Perindopril 68-79 angiotensin I converting enzyme Homo sapiens 53-56 3516512-10 1986 Thus in normotensive subjects, perindopril seems an effective, orally active, long-lasting ACE inhibitor. Perindopril 31-42 angiotensin I converting enzyme Homo sapiens 91-94 32916322-9 2021 The most commonly used angiotensin-converting enzyme inhibitor was perindopril (32.9% of the patients). Perindopril 67-78 angiotensin I converting enzyme Homo sapiens 23-52 3030762-0 1987 The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients. Perindopril 113-124 angiotensin I converting enzyme Homo sapiens 73-102 32410885-1 2020 Introduction: Perindopril is a tissue-specific ACE inhibitor with 24 hours long blood pressure-lowering effect, which protects blood vessels and decreases the variability of blood pressure. Perindopril 14-25 angiotensin I converting enzyme Homo sapiens 47-50 33072254-7 2020 Perindopril was stopped and the patient improved, concluding that ACE inhibitor-induced visceral angioedema was responsible for this clinical presentation. Perindopril 0-11 angiotensin I converting enzyme Homo sapiens 66-69 30573480-6 2018 METHODS AND ANALYSIS: We are conducting a multicentre, parallel group, randomised, placebo-controlled study of combination therapy with an ACE inhibitor (perindopril) and a beta-blocker (bisoprolol) in boys with DMD aged 5-13 years, with normal LV function by echocardiographic criteria at the time of recruitment. Perindopril 154-165 angiotensin I converting enzyme Homo sapiens 139-142 30535909-3 2019 We hypothesized that perindopril, an angiotensin-converting enzyme (ACE) inhibitor, indicated for the treatment of hypertension (Ceconi et al., in Cardiovasc Res 73:237-246, 2007), and which plays a role in preventing endothelial dysfunction, may help to prevent or reduce the severity of regorafenib-induced HFSR. Perindopril 21-32 angiotensin I converting enzyme Homo sapiens 37-66 30535909-3 2019 We hypothesized that perindopril, an angiotensin-converting enzyme (ACE) inhibitor, indicated for the treatment of hypertension (Ceconi et al., in Cardiovasc Res 73:237-246, 2007), and which plays a role in preventing endothelial dysfunction, may help to prevent or reduce the severity of regorafenib-induced HFSR. Perindopril 21-32 angiotensin I converting enzyme Homo sapiens 68-71 30942616-0 2019 The Effect of Angiotensin-Converting Enzyme Gene Polymorphisms on the Clinical Efficacy of Perindopril Prescribed for Acute Myocardial Infarction in Chinese Han Patients. Perindopril 91-102 angiotensin I converting enzyme Homo sapiens 14-43 30942616-1 2019 Objective: Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that is commonly used in the treatment of Chinese Han patients with acute myocardial infarction (AMI). Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 29-58 30942616-1 2019 Objective: Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that is commonly used in the treatment of Chinese Han patients with acute myocardial infarction (AMI). Perindopril 11-22 angiotensin I converting enzyme Homo sapiens 60-63 30942616-2 2019 However, there have been few studies on whether polymorphisms of the ACE gene affect the efficacy of perindopril or the prognosis of AMI patients. Perindopril 101-112 angiotensin I converting enzyme Homo sapiens 69-72 30942616-3 2019 The purpose of this study was to analyze the relationship among the ACE rs121912703 (C>T), rs767880620 (C>A), and rs397514689 (C>T) gene polymorphisms and the prognosis of AMI patients and the clinical efficacy of perindopril in the treatment of AMI. Perindopril 223-234 angiotensin I converting enzyme Homo sapiens 68-71 30942616-4 2019 Methods: The ACE genotypes at the rs121912703, rs767880620, and rs397514689 loci in 225 AMI patients treated with perindopril were determined by polymerase chain reaction/Sanger sequencing. Perindopril 114-125 angiotensin I converting enzyme Homo sapiens 13-16 30942616-6 2019 Results: After administration of perindopril, improved ventricular remodeling in AMI patients with wild-type ACE was better than in patients with the ACE rs121912703, rs767880620, and rs397514689 minor variant alleles. Perindopril 33-44 angiotensin I converting enzyme Homo sapiens 109-112 30942616-10 2019 Conclusion: Mutations at the ACE rs121912703, rs767880620, and rs397514689 loci affect the efficacy of perindopril on ventricular remodeling and hemodynamics in Chinese Han AMI patients. Perindopril 103-114 angiotensin I converting enzyme Homo sapiens 29-32 28840773-3 2017 ARPE-19 cells were treated with the angiotensin converting enzyme (ACE) inhibitor perindopril to block the synthesis of Ang II. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 36-65 29635787-4 2018 The results identify that perindopril, a centrally acting angiotensin converting enzyme inhibitor, markedly attenuates the central sympathetic outflow during acute and prolonged dynamic exercise. Perindopril 26-37 angiotensin I converting enzyme Homo sapiens 58-87 28840773-3 2017 ARPE-19 cells were treated with the angiotensin converting enzyme (ACE) inhibitor perindopril to block the synthesis of Ang II. Perindopril 82-93 angiotensin I converting enzyme Homo sapiens 67-70